US20100055065A1 - Agent for inhibiting production of hepatitis c virus and its use - Google Patents
Agent for inhibiting production of hepatitis c virus and its use Download PDFInfo
- Publication number
- US20100055065A1 US20100055065A1 US12/546,281 US54628109A US2010055065A1 US 20100055065 A1 US20100055065 A1 US 20100055065A1 US 54628109 A US54628109 A US 54628109A US 2010055065 A1 US2010055065 A1 US 2010055065A1
- Authority
- US
- United States
- Prior art keywords
- hcv
- pac
- agent
- hydroxyl
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 55
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 44
- 241000711549 Hepacivirus C Species 0.000 title claims abstract description 14
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 claims abstract description 148
- 229920001991 Proanthocyanidin Polymers 0.000 claims abstract description 148
- 230000000694 effects Effects 0.000 claims abstract description 80
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 43
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 41
- 229920000642 polymer Polymers 0.000 claims abstract description 38
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 34
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 23
- 239000001257 hydrogen Substances 0.000 claims abstract description 22
- 229930182497 flavan-3-ol Natural products 0.000 claims abstract description 18
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical group OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
- 239000001301 oxygen Substances 0.000 claims abstract description 7
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 50
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 49
- 235000021014 blueberries Nutrition 0.000 claims description 48
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 40
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical group OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 20
- 239000000178 monomer Substances 0.000 claims description 15
- 208000019423 liver disease Diseases 0.000 claims description 11
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 229940002612 prodrug Drugs 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 238000011161 development Methods 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 230000005727 virus proliferation Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- 230000010076 replication Effects 0.000 description 41
- 239000000523 sample Substances 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 238000000034 method Methods 0.000 description 27
- 238000004128 high performance liquid chromatography Methods 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 20
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 19
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 19
- 235000012734 epicatechin Nutrition 0.000 description 19
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 19
- 238000005194 fractionation Methods 0.000 description 19
- 239000003480 eluent Substances 0.000 description 18
- -1 pH regulator Substances 0.000 description 16
- 238000006116 polymerization reaction Methods 0.000 description 16
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 15
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 15
- 235000005487 catechin Nutrition 0.000 description 15
- 229950001002 cianidanol Drugs 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 235000013399 edible fruits Nutrition 0.000 description 14
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 14
- XFZJEEAOWLFHDH-NFJBMHMQSA-N procyanidin B2 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-NFJBMHMQSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 13
- 229920000124 Prodelphinidin Polymers 0.000 description 13
- 229930182448 Prodelphinidin Natural products 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 229920002414 procyanidin Polymers 0.000 description 13
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 13
- 238000007079 thiolysis reaction Methods 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 244000078534 Vaccinium myrtillus Species 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000000401 methanolic extract Substances 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical group C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 11
- 150000007524 organic acids Chemical group 0.000 description 11
- 102000014150 Interferons Human genes 0.000 description 10
- 108010050904 Interferons Proteins 0.000 description 10
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 230000003013 cytotoxicity Effects 0.000 description 10
- 229940079322 interferon Drugs 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 150000002206 flavan-3-ols Chemical class 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 244000205754 Colocasia esculenta Species 0.000 description 8
- 235000006481 Colocasia esculenta Nutrition 0.000 description 8
- RSYUFYQTACJFML-UKRRQHHQSA-N Epiafzelechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C=C1 RSYUFYQTACJFML-UKRRQHHQSA-N 0.000 description 8
- 229920002770 condensed tannin Polymers 0.000 description 8
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- 241000209524 Araceae Species 0.000 description 7
- 0 B.C.[1*]C1=CC(C2OC3=CC(O)=CC(O)=C3CC2C)=CC([3*])=C1[2*] Chemical compound B.C.[1*]C1=CC(C2OC3=CC(O)=CC(O)=C3CC2C)=CC([3*])=C1[2*] 0.000 description 7
- 235000016623 Fragaria vesca Nutrition 0.000 description 7
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 7
- 229920002350 Procyanidin B2 Polymers 0.000 description 7
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 7
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 7
- 235000004634 cranberry Nutrition 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 238000000252 photodiode array detection Methods 0.000 description 7
- 235000020004 porter Nutrition 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000004885 tandem mass spectrometry Methods 0.000 description 7
- 239000013638 trimer Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 244000168525 Croton tiglium Species 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 240000008424 Vaccinium ashei Species 0.000 description 6
- 235000013468 Vaccinium ashei Nutrition 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- LUFPJJNWMYZRQE-UHFFFAOYSA-N benzylsulfanylmethylbenzene Chemical compound C=1C=CC=CC=1CSCC1=CC=CC=C1 LUFPJJNWMYZRQE-UHFFFAOYSA-N 0.000 description 6
- 238000004453 electron probe microanalysis Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 235000018192 pine bark supplement Nutrition 0.000 description 6
- 229940106796 pycnogenol Drugs 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- TXLFUHUBGBCKNS-UHFFFAOYSA-N 2-[[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl]oxy]-2-(4-hydroxyphenyl)-3,4-dihydrochromene-3,4,5,7-tetrol Chemical group OC1C(O)C(OC2Cc3c(O)cc(O)cc3OC2c2ccc(O)c(O)c2)(Oc2cc(O)cc(O)c12)c1ccc(O)cc1 TXLFUHUBGBCKNS-UHFFFAOYSA-N 0.000 description 5
- 244000105624 Arachis hypogaea Species 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229920002783 Propelargonidin Polymers 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 5
- 235000020232 peanut Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 240000009088 Fragaria x ananassa Species 0.000 description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 240000001717 Vaccinium macrocarpon Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- RSYUFYQTACJFML-DZGCQCFKSA-N afzelechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C=C1 RSYUFYQTACJFML-DZGCQCFKSA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 4
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 235000007336 cyanidin Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- YYEFTOIQHQHUQZ-UHFFFAOYSA-N epicatechin-benzylthio ether Natural products OC1C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1SCC1=CC=CC=C1 YYEFTOIQHQHUQZ-UHFFFAOYSA-N 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 3
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241001448862 Croton Species 0.000 description 3
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 3
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 244000307700 Fragaria vesca Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000011430 Malus pumila Nutrition 0.000 description 3
- 244000070406 Malus silvestris Species 0.000 description 3
- 235000015103 Malus silvestris Nutrition 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 244000291414 Vaccinium oxycoccus Species 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 125000005233 alkylalcohol group Chemical group 0.000 description 3
- 229930014669 anthocyanidin Natural products 0.000 description 3
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 3
- 235000008758 anthocyanidins Nutrition 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 235000007242 delphinidin Nutrition 0.000 description 3
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 3
- 238000004807 desolvation Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 125000000962 organic group Chemical group 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000018262 Arachis monticola Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000006008 Brassica napus var napus Nutrition 0.000 description 2
- 229920002798 Cinnamtannin B1 Polymers 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920002752 Konjac Polymers 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 244000281247 Ribes rubrum Species 0.000 description 2
- 235000002355 Ribes spicatum Nutrition 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 244000177965 Vaccinium lamarckii Species 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000001046 cacaotero Nutrition 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 150000002243 furanoses Chemical class 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 150000002338 glycosides Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 150000002402 hexoses Chemical group 0.000 description 2
- JGPCLGHKWGCWNO-UHFFFAOYSA-O hirsutidin Chemical compound [O+]=1C2=CC(OC)=CC(O)=C2C=C(O)C=1C1=CC(OC)=C(O)C(OC)=C1 JGPCLGHKWGCWNO-UHFFFAOYSA-O 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 150000002972 pentoses Chemical group 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 150000003214 pyranose derivatives Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960004029 silicic acid Drugs 0.000 description 2
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- GYQDOAKHUGURPD-UHFFFAOYSA-N 5,7-Dihydroxy-2-(4-hydroxyphenyl)-1-benzopyrylium chloride Chemical compound [Cl-].C1=CC(O)=CC=C1C1=CC=C(C(O)=CC(O)=C2)C2=[O+]1 GYQDOAKHUGURPD-UHFFFAOYSA-N 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- ZKMZBAABQFUXFE-UHFFFAOYSA-O Apigeninidin Natural products C1=CC(O)=CC=C1C1=CC=C(C(O)=CC(O)=C2)C2=[O+]1 ZKMZBAABQFUXFE-UHFFFAOYSA-O 0.000 description 1
- VGONRPRFJVEJKB-UHFFFAOYSA-O Aurantinidin Chemical compound C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=C(O)C(O)=C2 VGONRPRFJVEJKB-UHFFFAOYSA-O 0.000 description 1
- 229920002330 B type proanthocyanidin Polymers 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 244000178937 Brassica oleracea var. capitata Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101710178035 Chorismate synthase 2 Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241001584859 Colocasia <moth> Species 0.000 description 1
- 101710152694 Cysteine synthase 2 Proteins 0.000 description 1
- 102100026816 DNA-dependent metalloprotease SPRTN Human genes 0.000 description 1
- 101710175461 DNA-dependent metalloprotease SPRTN Proteins 0.000 description 1
- 101100476962 Drosophila melanogaster Sirup gene Proteins 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000208421 Ericaceae Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229920001554 Procyanidin C1 Polymers 0.000 description 1
- 229920001019 Profisetinidin Polymers 0.000 description 1
- 229920002510 Proguibourtinidin Polymers 0.000 description 1
- 229920001826 Prorobinetidin Polymers 0.000 description 1
- 241000308676 Pterocarpus officinalis Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 235000016911 Ribes sativum Nutrition 0.000 description 1
- 235000016897 Ribes triste Nutrition 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 244000209710 Samanea saman Species 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 238000003120 Steady-Glo Luciferase Assay System Methods 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 235000012511 Vaccinium Nutrition 0.000 description 1
- 241000736767 Vaccinium Species 0.000 description 1
- 244000176769 Vaccinium canadense Species 0.000 description 1
- 235000013473 Vaccinium lamarckii Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229940126675 alternative medicines Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-M argininate Chemical compound [O-]C(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-M 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229930015058 aurantinidin Natural products 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- YYXCWZWITZTNRU-UHFFFAOYSA-N benzylsulfanylmethylbenzene;2-phenyl-3,4-dihydro-2h-chromen-3-ol Chemical compound C=1C=CC=CC=1CSCC1=CC=CC=C1.OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 YYXCWZWITZTNRU-UHFFFAOYSA-N 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- LMSNZLCSZWZZGU-UHFFFAOYSA-N butan-1-ol;hydrochloride Chemical compound Cl.CCCCO LMSNZLCSZWZZGU-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002116 epicatechin Chemical class 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 229930003487 europinidin Natural products 0.000 description 1
- XJXMPIWHBIOJSH-UHFFFAOYSA-O europinidin Chemical compound OC1=C(O)C(OC)=CC(C=2C(=CC=3C(OC)=CC(O)=CC=3[O+]=2)O)=C1 XJXMPIWHBIOJSH-UHFFFAOYSA-O 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002215 flavonoids Chemical group 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 239000001056 green pigment Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229930013978 luteolinidin Natural products 0.000 description 1
- GDNIGMNXEKGFIP-UHFFFAOYSA-O luteolinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=CC=1C1=CC=C(O)C(O)=C1 GDNIGMNXEKGFIP-UHFFFAOYSA-O 0.000 description 1
- 235000009584 malvidin Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- BNWJOHGLIBDBOB-UHFFFAOYSA-N myristicine Natural products COC1=CC(CC=C)=CC2=C1OCO2 BNWJOHGLIBDBOB-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- HKUHOPQRJKPJCJ-UHFFFAOYSA-N pelargonidin Natural products OC1=Cc2c(O)cc(O)cc2OC1c1ccc(O)cc1 HKUHOPQRJKPJCJ-UHFFFAOYSA-N 0.000 description 1
- 235000006251 pelargonidin Nutrition 0.000 description 1
- YPVZJXMTXCOTJN-UHFFFAOYSA-N pelargonidin chloride Chemical compound [Cl-].C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 YPVZJXMTXCOTJN-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229930015721 peonidin Natural products 0.000 description 1
- 235000006404 peonidin Nutrition 0.000 description 1
- OGBSHLKSHNAPEW-UHFFFAOYSA-N peonidin chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 OGBSHLKSHNAPEW-UHFFFAOYSA-N 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 229930015717 petunidin Natural products 0.000 description 1
- 235000006384 petunidin Nutrition 0.000 description 1
- QULMBDNPZCFSPR-UHFFFAOYSA-N petunidin chloride Chemical compound [Cl-].OC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 QULMBDNPZCFSPR-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000020741 pine bark extract Nutrition 0.000 description 1
- 229940106587 pine bark extract Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 125000004402 polyphenol group Chemical group 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- MOJZMWJRUKIQGL-XILRTYJMSA-N procyanidin C1 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C2=C3O[C@@H]([C@H](O)[C@H](C3=C(O)C=C2O)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 MOJZMWJRUKIQGL-XILRTYJMSA-N 0.000 description 1
- KNAPHRIACIMBNT-UHFFFAOYSA-N profisetinidin Natural products Oc1ccc2C3OC4C(Oc5cc(O)ccc5C4OC3C(Oc2c1)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1 KNAPHRIACIMBNT-UHFFFAOYSA-N 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- 229930002286 rosinidin Natural products 0.000 description 1
- GNONHFYAESLOCB-UHFFFAOYSA-O rosinidin Chemical compound [O+]=1C2=CC(OC)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(OC)=C1 GNONHFYAESLOCB-UHFFFAOYSA-O 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940100613 topical solution Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
Definitions
- This invention relates to an agent for inhibiting production of hepatitis C virus.
- this invention also relates to use of proanthocyanidin.
- Hepatitis C virus (hereinafter referred to as HCV) has been found as a major causal virus of non-A non-B hepatic inflammation after blood transfusion.
- HCV is a single-strand RNA virus having an envelope and belongs to Hepacivirus of Flaviviridae.
- HCV carriers progress directly to chronic hepatitis without acute hepatitis and then to cirrhosis after many years. About 50 percents of HCV carriers go onto the development of hepatocellular carcinoma. It is said that main cause of such development is persistent infection with HCV. The persistent infection tends to occur even in adults who were infected with HCV after establishing immune system. Even in case of a patient whose site or sites of hepatocellular carcinoma has been completely removed by surgery, the patient still remains at high risk of recurrence, result of the persistent infection repeatedly occurred in unremoved sites.
- WO2004/047847 refers to an antiviral action of proanthocyanidin and suggests that the proanthocyanidin might be usable for treating hepatic inflammation. Nevertheless, the antiviral action in the publication is against West Nile virus of Flaviviridae. Although HCV belongs to same family, it differs from the West Nile virus in taxonomic genus and the site of infection. The publication has no suggestion as to inhibitory activity of proanthocyanidin for production of HCV.
- U.S. Pat. No. 5,211,944 disclosed that a proanthocyanidin polymer composition having 2 to 11 flavonoid units is specifically useful for treating respiratory virus infection such as respiratory syncytial virus, influenza virus and parainfluenza virus infection, but the respiratory virus is quite different from HCV. So, the publication dose not drop any hint about possible activity of proanthocyanidin against HCV production.
- interferon therapy is only effective method for inhibiting production or proliferation of HCV, or eliminating HCV. Even so, around 50 percents of the HCV carriers still remain at risk for onset of hepatocellular carcinoma due to failure to clean HCV completely. It is also suggested that interferon should be administered together with ribavirin to enhance disappearance rate of HCV. Further, continuous dosing of interferon in a low dose has been introduced to inhibit progress of hepatitis C disease and then to retard eventually the onset of hepatocellular carcinoma.
- An object of this invention is to provide an agent for effectively inhibiting production of HCV with fewer side-effects.
- Another object of this invention is to provide an agent for inhibiting onset, progress and treating of hepatic disease arisen from HCV.
- Further object of this invention is to provide dietary supplements for inhibiting onset or progress of hepatic disease arisen from HCV.
- An aspect of this invention resides in an agent for inhibiting production of HCV comprising a proanthocyanidin polymer composition.
- the proanthocyanidin polymer composition has a structure in which flavan-3-ols illustrated in the general formula (1) are bound each other through any of the bond pattern (i), (ii) and (iii) mentioned below.
- the proportion of flavan-3-ol in which both R 1 and R 3 are hydroxyl is at most 40 percents.
- R 1 is hydrogen or hydroxyl
- R 2 is hydroxyl
- R 3 is hydrogen when R 1 is either hydrogen or hydroxyl
- R 3 is possibly hydroxyl when R 1 is either hydrogen or hydroxyl to the extent that both R 1 and R 3 being hydroxyl is at most 40 percents in the proanthocyanidin polymer composition
- R 4 is hydrogen or a univalent organic acid group.
- the agent for inhibiting HCV production comprising the proanthocyanidin with the structure aforementioned has advantages of fewer side-effects, dosing over a long period of time and effective anti-HCV production activity.
- R 4 in the general formula (1) is preferably a gallate group allowed to have substituent groups.
- the ratio of the concentration of proanthocyanidin polymer composition inhibiting 50 percents of HCV virus proliferation (IC50) divided by the concentration of proanthocyanidin polymer composition inhibiting 50 percents of cell proliferation (CC50) is desirably at most one tenth.
- Such an inhibiting agent of HCV production has fewer side-effects and can be dosed for a long period of time.
- the HCV production inhibitor of this invention has the structure in which proanthocyanidin polymer composition has preferably flavan-3-ol unit of the general formula (1) bound each other in any one of the bond pattern (i), (ii) or (iii).
- Another aspect of this invention resides in an agent or a prodrug for treating the hepatic disease arisen from HCV.
- Another aspect of this invention resides in an agent or a prodrug for inhibiting onset or progress of the hepatic disease arisen from HCV.
- a dietary supplement including food or drink for inhibiting onset, progress or treating of the hepatic disease arisen from HCV.
- the agent for inhibiting production of HCV has advantages of significant anti-HCV activities with fewer side-effects and a long dosing period of time.
- the inhibiting agent of HCV production comprising the proanthocyanidin has less cytotoxicity in addition to higher anti-HCV replicon proliferation in vitro. It is, therefore, useful for alternative medicines or dietary supplements instead of interferon.
- the agent has also advantages to be able to dose continuously for a longer period of time, owing to fewer side-effects compared with interferon. In case of the patients having cirrhosis or hepatocellular carcinoma, numbers of platelets or leucocytes are so small that they would be unable to receive continuously the interferon therapy.
- the therapy using the agent of this invention can, therefore, become an effective alternative therapy for interferon.
- the proanthocyanidin is useful for a functional dietary supplement including food or drink as well.
- FIG. 1 shows HCV replication suppressive activity of PAC from blueberry leaves in replicon cells.
- FIG. 2A shows HPLC chromatogram of methanol extract from blueberry leaves.
- FIG. 2B shows the replication suppressive activity of fractionation by HPLC according to FIG. 2A .
- FIG. 3A shows HPLC chromatogram of 1st fractionation (LC1) of methanol extract from blueberry leaves.
- FIG. 3B shows the replication suppressive activity of LC1 by HPLC according to FIG. 3A .
- FIG. 4A shows HPLC chromatogram of 2nd fractionation (LC2) of LC1.
- FIG. 4B shows the replication suppressive activity of LC2 by HPLC according to FIG. 4A .
- FIG. 5A shows HPLC chromatogram of 3rd fractionation (LC3) of LC2.
- FIG. 5B shows the replication suppressive activity of LC3 by HPLC according to FIG. 5A .
- FIG. 6 shows elemental composition analysis of LC3 (purified fraction from blueberry leaves) by electron probe micro-analysis (EPMA)
- FIG. 7 shows mass spectrum of LC3 (purified fraction from blueberry leaves) by LC/APCI-MS-IT-TOF
- FIG. 8A shows MS/MS spectrum of cyanidin preparation by LC/ESI-MS.
- FIG. 8A shows MS/MS spectrum of LC3 (purified fraction from blueberry leaves) by LC/ESI-MS.
- FIG. 9 shows thiolysis reaction pattern of PAC reacted with benzylmercaptan under acidic condition.
- FIG. 10 shows reverse-phased HPLC chromatogram of thiolysate from LC3 (purified fraction from blueberry leaves).
- FIG. 11 shows the relationship with mean degree of polymerization (mDP) and specific activity (1/IC50) of Sephadex LH-20 fractionation from blueberry leaves.
- the inhibitory agent for production of HCV in this invention comprises a proanthocyanidin polymer composition (herein after referred to as PAC).
- the PAC in this invention is a polymer composition of matter wherein the monomer unit in the general formula (1) is combined each other in three bond patterns below.
- the number of monomer unit defining the polymerization degree of PAC is at least 3, preferably at least 5, more preferably 5 to 10.
- the typical bond patterns of the monomer unit are described bellow.
- R 1 is hydrogen or hydroxyl
- R 2 is hydroxyl
- R 3 is hydrogen when R 1 is either hydrogen or hydroxyl
- R 3 is possibly hydroxyl when R 1 is either hydrogen or hydroxyl to the extent that both R 1 and R 3 being hydroxyl is at most 40 percents in the proanthocyanidin polymer composition
- R 4 is hydrogen or a univalent organic group respectively.
- the organic acid may be p-coumarin acid, caffeic acid, ferulic acid, sinapic acid, p-hydroxyl benzoic acid, gallic acid, acetic acid, oxalic acid, malonic acid, succinic acid, malic acid and so on.
- R 4 may also be glycoside residue in which sugars are bound with organic acid residue or gallate groups.
- the sugars are bound with a phenolic hydroxyl of the gallate groups or the organic acid groups through ester bonds at any position.
- the sugars may be monosaccharide including glucose, galactose, rhamnose, xylose and arabinose, and either disaccharide or trisaccharide.
- R 4 is preferably a gallate group permitted to have substituent groups consisting of a gallate group or a gallate group with substituent.
- the gallate group with substituent includes a gallate group with which sugar are bound.
- each hydroxyl of A-ring at the position 5 and/or the position 7 may be replaced by modified groups such as a gallate group, sugar, organic acid and the like.
- the proportion of flavan-3-ol of which both R 1 and R 3 are hydroxyl is at most 40 percents. In case the proportion is more than 40 percents, it is insufficient to suppress production of HCV.
- the proportion can be measured by thiol cleavage method.
- one of the PAC of this invention cab be illustrated in the general formula (2), wherein flavan-3-ol units are bound each other at the bond pattern (i).
- R 1 and R 3 are hydrogen or hydroxyl
- R 2 is hydroxyl
- R 4 is oxygen or a univalent organic group, provided that the proportion of both R 1 and R 3 being hydroxyl is at most 40 percents.
- Only such a PAC polymer composition can express suppressive activity of the HCV replication in this invention. While the PAC polymer composition wherein the proportion of both R 1 and R 3 being hydroxyl is more than 40 percents cannot meet the criterion level of the suppressive activity of HCV replication in this invention.
- position 5 and/or 7 of A-ring in the monomer unit of the general formula (1) is hydroxyl
- at least one of them may be a univalent modified group bound therewith.
- Typical modified groups may be a gallate group, sugar or organic acid.
- the anti-HCV production activity is actually an activity for inhibiting the replication of HCV replicon cell in vitro, and can be expressed as anti-HCV production activity value (IC50; ⁇ g/ml) or the ratio between the anti-HCV production activity value (IC50; ⁇ g/ml) and the cytotoxicity value (CC50; ⁇ g/ml). It is desirable that the anti-HCV production activity value (IC50; ⁇ g/ml) is at most 1.0; ⁇ g/ml in terms of the IC50 of interferon.
- cytotoxicity activity value CC50; ⁇ g/ml
- anti-HCV production activity value IC50; ⁇ g/ml
- the effect of PAC in this invention can be evaluated with the ratio.
- PAC is a kind of the condensed tannin contained in various plants, and can be treated by acids to give cyanidin, delphinidin, pelargonidin, aurantinidin, luteolinidin, peonidin, malvidin, petunidin, europinidin, rosinidin, hirsutidin, apigeninidin and so on.
- the PAC belongs mainly to catechin class, namely, polyphenol groups consisting of condensation polymer, of which polymerization degree of the flavan-3-ol units is at least 2.
- R corresponds to OR 4 set forth above.
- a gallic acid is often bound with hydroxyl at the position 3 of flavan-ring through an ester-link.
- PAC can be said to be a generic term including various compositions of matter formed by polymerization of the flavan unit which has hydroxyl at some binding positions.
- the rear anchor is referred to as ‘terminal unit’ and the other units ‘extension unit’.
- a polymerization degree of the units extends over the wide range from dimmer to polymers having 100 units or more.
- Some polymers in which specified monomer is polymerized are called trivial names.
- the typical trivial names defined or classified depending on numbers of hydroxyl in B-ring of the flavan units are properalgonidin (4′-OH), procyanidin (3′-OH, 4-OH) or prodelphinidin (3′-OH, 4′-OH, 5′-OH).
- proguibourtinidin, profisetinidin and prorobinetinidin all of which has no hydroxyl at position 5 of A-ring of the flavan units.
- proteracacidin promelacacidin, proluteolinidin and so on.
- the PAC comprises proanthocyanidin, properalgonidin and/or prodelphinidin.
- the constituent units of procyanidin may be either one or more of same or different groups, and at least one selected from the group consisting of catechin, epicatechin, catechin gallate and epicatechin gallate.
- the constituent units of prodelphinidin can also be either one or more of same or different groups, and at least one selected from the group consisting of gallocatechin, epigallocatechin, gallocatechin gallate and epigarocatechin gallate.
- R 4 of the PAC in the general formula (1) is residues of the univalent organic acid, such as a gallate group, residue of sugar, residue of organic acid, wherein term ‘residue’ means a univalent group or groups caused by losing atom or group in the molecular.
- organic acid in the organic acid residues there are p-coumaric acid, caffeic acid, ferulic acid, sinapic acid, p-hydroxyl benzoic acid, gallic acid, acetic acid, oxalic acid, malonic acid, succinic acid, and malic acid and so on.
- Sugar in the sugar residue may be bound with the hydroxyl of phenol in any binding position thereof through an ester bond to modify.
- the residues constituting glycoside may be hexose residue of pyranose form and pentose residue of furanose form.
- monosaccharide including glucose, galactose, rhamnose, xylose, arabinose etc., and other disaccharide or trisaccharide.
- the main binding positions among units constituting the PAC are (i) (ii) or (iii) set forth above.
- A-type bond consisting of both the bond of carbons at the position 4 and 8
- B-type bond consisting of either the bond of carbons at the position 4 and 6, or bond of carbon at the position 4 and 8.
- the PAC as illustrated in the general formula (3) and (4) has A-type bond and B-type bond. According to the findings of the inventors, however, the difference in the extension of A-type bond and B-type bond, or the mixture ratio therebetween does not affect the anti-HCV production activity of the PAC.
- the PAC extracted from blueberry both of the polymerization degree and the proportion of hydroxyl in B-ring in the PAC polymer composition must meet the criterion of this invention, though the B-type bond is dominant.
- PAC polymer compositions such as steric conformation of substituent groups in flavan unit and binding order among a variety of flavan units.
- the chemical names of the PAC in this invention are listed as follows. The letters in parentheses express chemical formula.
- This invention may encompass PACs of higher polymerization degrees, which are polycondensated with constituent units such as catechin and epicatechin, or with other proanthocyanidin.
- the mean polymerization degree of the PAC is preferably at least 5 in terms of anti-HCV production activity as shown in FIG. 11 .
- a PAC polymer composition contains at least 3 of monomer unit of the general formula (1) in the mean polymerization degree; its anti-HCV replicon production activity value is at most 1.0 ⁇ g/ml; the ratio of cytotoxicity activity value (CC50) divided by anti-HCV production activity value (IC50) is at least 10, such PAC polymer compositions are covered in this invention.
- the mean polymerization degree of the PAC means the average number of flavan-3-ol units bound each other with the bond pattern (i), (ii) and (iii).
- the number of flavan units can be determined by the method described in the example 1.
- the PAC may be either synthetic product or natural product.
- the natural product can be derived from some plants containing polyphenol. It is known that some colored fruits and vegetables are high content of polyphenol.
- the blueberry leaves, the grape seeds and taro are very effective for the inhibitory activity of HCV production.
- the skin of Taro contains a large amount of proanthocyanidin. It may be practical to use the skin of Taro, in spite of the unsuitable part for eating.
- the usable starting material is, for example, leaves, petals, calyx, flowers, leafstalks, fresh tops, roots, stems, seeds, pods, rhizomes, barks, cambiums, lumbers, mycocecidium, fruits, tree saps, resin, a peel of grape, apple, onion, avocado and citrus; pomas of apple, wine, grain hull, straw and hay; the lumps from oily seeds derived from olive, oilseed rape and canola; and the extracts from other oily crops etc.
- the most preferable starting material is blueberry shown in the example 1.
- the blueberry belonging to Cyanococcus of Vaccinium of Ericaceae is a deciduous or evergreen fruit tree, which is a low tree or a low bushes originally comes from America.
- the Usable blueberries in this invention are without reference to kinds and native localities thereof and are limited to the listed above.
- the blueberry is generally classified into around six kinds, among which the routine use of horticulture is said to be three kinds below.
- Rabbiteye blueberry is most useful staring material among them listed above.
- the PAC as effective ingredient in this invention can be produced by combination of following steps depending on intended use.
- the distillate may be supplied to next step directly or after pulverizing with or without drying. Extracted or squeezed juice from the crude material can also be supplied as well. Before supplying next step, the extracted or squeezed juice may be condensed, dried and pulverized into powder.
- any conventional dryer can be used in this invention, so long as changing nature of chemicals in the crude material.
- a vacuum-freeze dryer a hot air dryer, a far-infrared radiation dryer, a reduced-pressure dryer, a micro-wave reduced-pressure dryer, a super-heated steam dryer etc.
- the vacuum-freeze dryer is more useful, because of having few effects on the nature of the chemicals.
- the Vacuum-freeze dryer should be used under the designated condition depending on the state of leaves to be processed. For example, in case of fresh leaves, it is desirable that freezing temperature is from ⁇ 30 to ⁇ 20° C.; drying temperature from ⁇ 30 to 30° C.; and drying period 15 to 24 hours.
- Extract step The processed material in the former steps is then extracted with a solvent or solvents through single or multiple steps.
- the solvents may be used either alone or the combination thereof.
- water or polar solvent compatible with water can be preferably used.
- the solvent compatible with water there are lower alkyl alcohol with numbers of carbon 1 to 4, such as methanol, ethanol, propanol, butanol etc. and polyol such as ethylene glycol, butylene glycol, propylene glycol, glycerin etc.
- lower alkyl alcohol such as methanol or ethanol may be practical in terms of safety.
- organic solvent such as acetone, diethyl ether, dioxane, acetonitrile, ethyl acetate, xylene, chloroform, toluene, hexane etc.
- these solvents may be used in either single or the combination thereof, such as the combination of water and polar solvent compatible with water.
- the mixed solvent of acetone and ethyl ether can be used preferably in the ratio of 1:1 by v/v. It is general to use the mixture of water and polar solvent as the mixed aqueous solvent.
- aqueous alkyl alcohol aqueous methanol and ethanol may be preferably used.
- the alcohol content in the aqueous alcohol is in the range of 5 to 90 percents, preferably 30 to 90 percents, more preferably 50 to 90 percents. It is recommended to use mixed alcohol solvent containing water or acetone in this invention.
- the processed material in above steps is immersed in cool or warm solvent. It is usually extracted under warming and agitating and then filtrated to give extracted liquid.
- the extraction may be preferably carried out using an aqueous alcohol solvent containing 80 volume percents of alcohol at room temperature and for immersion periods of 30 to 60 minutes depending on the extracting temperature. The extraction can be done by percolation method too.
- the impure solid materials can be removed from the obtained extract by filtration or centrifugal separation to give pure filtrate, if needed.
- the filtrate may be supplied to the next step directly, or after partially condensed by distillation or dried. Further, these condensed or dried materials can be further purified by the method such as column method or fractionation method with solvent (See; WO2000-64883).
- Taro Colocasia esculenta Schott
- Colocasia esculenta Schott usable in this invention as one of the material of the PAC belongs to Colocasia , Araceae, originated from the South Asia and is widely cultivated in the many varieties over the world.
- the root stocks and leaf stems have been mainly utilized for foodstuffs so far.
- araceae there is konjac ( Amorphophallus konjac ), which can be used as foodstuff after processing.
- araceae there are several varieties in araceae for appreciation too.
- the root stock of Araceae plants contains mucin, galactan and potassium as effective ingredients. It is also reported that galactan has activity of brain cell and immunity. Potassium prevents high blood pressure due to removing sodium. But there have been no report on anti-HCV production activity of the root stock of Araceae plants until now.
- the root stocks of Araceae plant are generally used after processing in this invention to realize effective anti-HCV production.
- typical processing method of the root stocks there are pulverization, dried pulverization, squeezation and solvent extraction.
- the root stocks are pulverized after drying or slicing before drying.
- the root stocks of Araceae can be dried according to the drying method of blueberry leaves set forth above.
- the extraction process and purification process can also be carried out by the same way as blueberry leaves.
- the PAC in this invention can be prepared into various formulations such as extracted solution, condensed solution, paste, and dried or semidried powder.
- the purified PAC is understandably higher anti-HVC production activity compared with crude extracts.
- HCV replicon cell as known in vitro evaluation system of HCV replication (Lohmann V. et al., Science Vol. 285, p. 110-113, (1999)) is employed as alternative vivo evaluation method.
- HCV replicon cell comprises a structural protein translation region with core and envelop constituting virus particle, and non-structural protein translation region having function of virus genome replication etc.
- the HCV replicon cell may be made from the non-structural region.
- the replication of HCV-RNA in this system is measured as replication numbers of whole HCV-RNA infected with HCV.
- the effective mean degree of polymerization (mDP) of the flavan unit in general formula (1) is at least 3 in integer value.
- This invention encompasses PAC polymer composition wherein the position R 2 of flavan unit in the general formula (1) is hydroxyl; the position R 1 and the position R 3 are hydrogen or hydroxyl; and the position R 4 is hydrogen or modified groups, so far as the proportion of both R 1 and R 3 being hydroxyl is at most 40 percents of whole polymer composition.
- the anti-HCV production activity of gallocatechin and epigallocatechin so called generally prodelphinidin wherein all the position R 1 , R 2 and R 3 in B-ring of the flavan unit are hydroxyl is likely quantity dependant inverse proportion as illustrated in the table 2.
- the polymer composition is unusable in practice as the inhibitor of HCV production in this invention.
- the PAC of this invention may be produced chemically or biologically.
- the PAC is also purified directly from the natural material such as plants, provided that its structure and function fall within the scope defined in this invention.
- the PAC may be supplied to end users in various formulations such as extracted solution, condensed solution, and dried or semidried powder etc. depending on their request.
- the inhibitory agents of HCV production in this invention may be available directly, or as either prodrug or formulated medicine.
- the PAC may be administered to persons infected with HCV, in the form of either polymer composition alone as shown in the general formula (1), or together with medically acceptable salts, hydrates and solvates. In general, it seems to be rather effective to dose a drug comprising the PAC and pharmacologically and pharmaceutically acceptable additives.
- pharmacologically and pharmaceutically acceptable additives there may be diluent, disintegrant, auxiliary disintegrant, binder, lubricant, coating, pigment, base agent, solvent, auxiliary solvent, isotonic agent, pH regulator, stabilizer, injection agent, adhesive and so on.
- the PAC When using the PAC as a drug, it is desirable to administrate in every dosing unit.
- dosing manner there are oral administration, enteral administration, intravenous administration, local administration such as dermal administration, and interstitial administration such as subcutaneous administration, intramuscular administration etc.
- solid dosage formulation for oral administration there may be tablet, ball, capsule, subtle granule or pill.
- emulsion, suspension, and syrups as liquid dosage formulation for oral administration.
- lubricant, colorant, flavoring agent, and/or pH regulator can be added to the base agent including the PAC.
- the tablet may be coated with conventional sugar coating, gelatin coating, enteric coating tablet, film coating, double coating and multiple coating, if required.
- diluents such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, hydrated silica etc.
- binders such as water, ethanol, propanol, sirup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinyl pyrolidone etc.
- disintegrants such as dried starch, sodium argininate, agar powder, laminarin powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose etc.
- disintegrant suppressing agent such as sucrose, stearin, cacao butter, hydrogenated oil etc.
- adsorption promoter such as quaternary ammonium salts, sodium lauryl sulfate etc.
- injectable products As the enteral administration, there may be the use of injectable products.
- injectable products When preparing the injectable products, it can be made in formulation of nontoxic solution, suspension or emulsion preferably sterilized and adjusted to the isotonicity nearly equal to blood.
- These suspension and emulsion can be prepared by using water; ethanol, propylene glycol, ethoxyisostearyl alcohol, polyoxyisosteayl alcohol etc; and/or polyoxyethylene sorbitan fatty acid ester. Further, there can be added sufficient amounts of salt, glucose and/or glycerin etc so as to obtain isotonic solution.
- solubilizing agents, buffering agents, pH regulating agents, soothing agents and the like can also be used.
- the injectable product can be administered under skin, into muscle or vein.
- topical solution cream, powder, paste, gellant and ointment.
- topical solution cream, powder, paste, gellant and ointment.
- PAC pharmacologically and pharmaceutically acceptable prodrug or salts
- additive usable for topical medicine such as fragrance, colorant, filler, surfactant, humectant, emollient, gellant, carrier, preserving agent and/or stabilizer.
- a suppository For the formulation of interstitial administration, a suppository is typical.
- higher alcohol higher ester such as myristicin palmitate ester, polyethylene glycol, cacao butter, gelatin, semi synthetic glyceride and their mixture as substrates with low melting point.
- the suppository can be formulated by adding the PAC, its prodrug and their medically acceptable salt to these substrates.
- the effective dosing quantity should be determined in view of condition of each patient of which condition are, for instance, a time of life, weight, the route of administration, the nature or level of disease etc.
- condition are, for instance, a time of life, weight, the route of administration, the nature or level of disease etc.
- the effective dosing quantities may be within the range of 1 to 2000 mg per a day for an adult human. But, according to clinical condition of a patient, the effective dosing quantities may be less than or larger than the suggested range. When dosing larger quantities than the suggested range, it is desirable to dose fractionally at several times per a day.
- the agent of this invention can also be adopted for preventing or inhibiting onset or progress of hepatic inflammation and cirrhosis, or treating hepatitis diseases arisen from HCV, in addition to the inhibition of HCV production that is the primary activity of this invention.
- the effective quantity of administration to a patient can not be determined strictly owing to variable dependant on the expected effect of treatment, administration method or its root, dosing periods, gender of a patient, and other condition of disease.
- the dosing quantities of the anti-HCV inhibitor including crude or purified production of this invention may be selected from the range about 100 to 1000 mg per a dose for the weight of 60 kg in a human patient as reduced weight of the purified PAC of this invention.
- the content of the PAC in the agent may be selected from the range of 0.1 to 99.5 weight percents, preferably 0.5 to 90 weight percents, though the content is needed not to specifically limit, because of variable dependant on the dosing quantities.
- the agent of this invention can be dosed. But, it is effective to dose in acute or chronic stage of hepatitis inflammation or stage of cirrhosis during which the state of hepatic disease is in progress.
- the PAC of this invention may be usable for dietary supplements such as food or drink.
- the supplements can be prepared in solid, liquid solution, emulsion and so on, and shaped into various forms such as tablet, ball, capsule, granule, powder, pastille, cake, drink etc.
- pharmacologically, pharmaceutically and dietary acceptable additives can be added.
- the additives include other various medical substances or functional ingredients such as vitamin, other minor components and the like.
- percent (%) means weight percent (w/w %), unless otherwise stated.
- HCV replication suppressive activity test replicas assay
- cytotoxicity test were carried out as follows.
- the HCV-replicon cell line was established by transducing sub-genomic RNA into human hepatoma Huh-7 cell cytoplasm.
- the sub-genomic RNA was prepared by replacing the translated region of HCV genome RNA structural proteins with firefly luciferase gene, internal ribosome entry site (IRES) of the encephalomyocarditis virus and neomycin phosphotransferase gene.
- the cell line obtained was used for assessment of production of HCV replicon RNA.
- the production quantity of HCV replicon RNA was measured by the luciferase assay method. (Lohmann et al., Science 285, (1999) 110; Sakamoto et al. Nat. Chem. Biol. 1, (2005) 333)
- luciferase genes from firefly were transduced into HCV-RNA as a reporter gene.
- the gene transduction was carried out according to the method of Krieger et al. (See; Krieger et al. J. virol. 75, (2001) 4614) in such manner that luciferase genes were fused together neomycin-resistant genes beneath the IRES of HCV gene.
- the replication efficiency of HCV could be estimated by measuring luciferase activity in the HCV replicon cells.
- the HCV replicon cells used were routinely grown in DMEM (Gibco cat. No. 10569-010) supplemented with Glutamax (Invitrogen), 10% fetal bovine serum (FBS), 1% penicillin/streptomycin (Invitrogen) and 500 ⁇ g/ml G418 (Invitrogen). The cells were maintained at 37° C. in humidified atmosphere containing 5% CO2.
- the replicon cells in DMEM supplemented with Glutamax and 5% FBS were seeded in a 96-well plate so as to fill every well with 5000 cells, and incubated for 24 hours.
- the test was carried out in such a way that the HCV replicon cells were cultured for 72 hours after adding test samples in different concentrations.
- the Quantity of the luciferase activity was determined by the Steady-Glo Luciferase Assay System (Promega) according to the manufacture's instructions and the luminescence was measured by DTX 800 Multimode Detector (Beckman).
- the replication inhibitory activity is expressed as a concentration of samples required for inhibiting 50 percents of the replication of HCV replicon cell (IC50).
- Specific activity is a reciprocal number of IC50 (1/IC50). Total activity is calculated by multiplying the yield weight of the HCV replicon cell by specific activity.
- the cytotoxicity of the samples was measured by Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies) according to the manufacture's instructions. Briefly, 10 ⁇ l/a well of CCK-8 reagent were added to the HCV replicon cells cultured in a 96-well plate and then incubated at 37° C. for 60 min. The absorbance of each well was measured at 450 nm with a reference wavelength at 650 nm using an Emax Precision microplate reader (Molecular Devices Inc.). Cell viability was calculated as relative index of control cells and effects of samples and was expressed as the concentration of samples required for 50% cytotoxicity of the cells (CC50).
- CCK-8 Cell Counting Kit-8
- FIG. 1 illustrates the results of a PAC sample from blueberry leaves in replicon assay.
- the IC50 value showing the replication suppressive activity was 0.56 ⁇ g/ml and the CC50 value showing the cytotoxicity was 16.26 ⁇ g/ml.
- the IC50 was less than or equal to 1.0 ⁇ g/ml and the ratio, which was calculated by dividing CC50 by IC50, was larger than or equal to 10.
- the PAC sample has the inhibitory activity of HCV replication.
- the supernatant was mixed with 150 ml of distilled water and methanol to perform a liquid-liquid extraction, and the water layer was collected and mixed with 150 ml of chloroform so as to repeat the chloroform extraction.
- the water layer was concentrated and lyophilized (CMW-W: 284.2 mg).
- the chloroform layer was also concentrated and lyophilized (CMW-C, 56.3 mg).
- the suppressing activity of HCV replication was not detected from the CMW-C fraction in replicon cell assay, but detected from the CMW-ppt and the CMW-W. In following purification, the CMW-W with a large recovered amount in weight and a large amount of total activity was used.
- FIGS. 2 (A) and (B) shows HPLC chromatogram and activity of suppressed replication for collected fraction, respectively.
- the data indicated that a fraction having strong replication inhibitory activity and eluted by around 90% of acetonitrile at 17 min contains some week inhibitory activity fractions same as broadly eluted fraction earlier.
- Those results suggested the possible existence of multiple replication inhibitors in CMW-W fraction.
- the chlorogenic acid and the rutin included lots in blueberry leaves and eluted at around 6 and 11 min respectively were seem not to have the inhibition activity aforementioned.
- FIG. 3 shows the results of HPLC chromatogram and replicon assay in the collected fractions.
- the CM was separated into isocratic condition at 30% acetonitrile and the eluate from 3.3 to 5.2 min, and then the latter was collected. After repeating collection, 140.2 mg as active fraction (LC1) was obtained from 440 mg of methanol extracts. The IC50 value of this fraction in the HCV replication assay was 0.89 ⁇ g/ml and the yield of specific activity was 6-fold higher than that of the initial methanol extracts (TABLE 2).
- the active fraction (LC1) of 140.2 mg obtained from 1st fractionation was dissolved in 11 ml of methanol. The solution obtained was injected into HPLC system. The eluted fraction was collected from 2.1 to 18 min (Total 26 fractions).
- FIG. 4 shows HPLC chromatogram and replicon assay of collected fractions.
- FIG. 5 shows HPLC chromatogram and replicon assay of collected fractions.
- the active fraction was eluted during from 3.2 to 6.2 min and collected (LC3).
- the finally yielded solid material of 2.9 mg had a dark flesh color.
- TABLE 2 shows an overall purification steps from blueberry leaves. From 1000 mg of lyophilized powder of the leaves, 440 mg of methanol extracts were obtained. The IC50 value of methanol extracts was 5.47 ⁇ g/ml. From the 284.2 mg of the CMW-W fraction was found out the replication inhibitory activity wherein the IC50 value was 1.74 ⁇ g/ml; the specific activity of the CMW-W was 3-fold greater than that of the initial extracts; and the yield of the activity exceeded 200%. These values result from that the interfering substances had been removed from the test sample.
- the final fraction which was purified by repeated fractionation in reversed-phase HPLC showed a 63-fold increase in specific activity compared with the initial methanol extracts.
- the CC50 value of the cytotoxicity of LC3 was 18.5 ⁇ g/ml and the ratio was 212.6 that was a 16.5-fold higher ratio compared with initial extracts.
- EPMA EPMA-1600, Shimadzu
- the excitation voltage and the beam current were kept at 15 kV and at 100 nA, respectively.
- the diameter of the electron beam was 50 ⁇ m and the sample was processed for carbon shadowing in advance.
- the purified fraction LC3 was analyzed by EPMA. This analysis indicates that the fraction is composed of carbon, oxygen and hydrogen, but not nitrogen ( FIG. 6 ).
- Detector B Atmospheric pressure chemical ionization (APCI)-MS (Negative-ion Mode; interface voltage, ⁇ 3.0 kV, interface temperature, 450° C.; curved desolvation line (CDL) temperature, 200° C.; nebulizer N2 gas, 2.0 L/min; drying N2 pressure, 70 kPa; heat block temperature, 200° C.)
- APCI Atmospheric pressure chemical ionization
- CDL curved desolvation line
- the electrospray ionization (ESI) was used as ionized probe, but the target compounds were not able to observe in mass spectrum.
- ESI electrospray ionization
- the mass spectrum data shows five peaks ( FIG. 7 ).
- the [M-H] ⁇ at m/z 401.0494 and 689.1135 were considered to be trifluoroacetic acid adducts of m/z 287.0553 and 575.1196 respectively.
- the isolate was composed of one or more polymers of procyanidin.
- Heating PAC under acidic condition, carbenium ion and catechin are produced by disconnecting the interflavan-bond thereof.
- the former are more oxidized to give a red anthocyanidin.
- the porter method based on the principle of these color reaction is able to perceptively detect PAC from samples in increasing absorbance at 540 nm.
- Detector B ESI-MS (Positive-ion Mode; interface voltage, 4.5 kV, interface temperature, 200° C.; curved desolvation line (CDL) temperature, 200° C.; nebulizer N2 gas, 1.5 L/min; drying N2 pressure, 200 kPa; heat block temperature, 200° C.)
- the purified LC3 fraction was analyzed by Porter method.
- the reacted solution turned a red color, which corresponds to the color of anthocyanidin generated by heating of procyanidin/proanthocyanidin mixture under acidic conditions.
- procyanidin B2 as the standard, the procyanidin content in the LC3 fraction was 86.33%.
- the hydrolysis solution was analyzed by LC/MS-IT-TOF.
- LC/MS-IT-TOF was also employed in a negative ion mode.
- the instrument and analysis condition show as follows.
- Detector B ESI-MS (Negative-ion Mode; interface voltage, ⁇ 3.0 kV, interface temperature, 200° C.; curved desolvation line (CDL) temperature, 200° C.; nebulizer N2 gas, 1.5 L/min; drying N2 pressure, 200 kPa; heat block temperature, 200° C.)
- Flavan-3-ols and their benzylthio adducts obtained by thiolysate of procyanidin B2 was used as a standard.
- FIG. 9 shows the basic reaction of thiolytic cleavage. In thiolytic reaction, the PAC was reacted with benzylmercaptan under the acidic condition so that the extension units of PAC were released to the corresponding benzylthioether and the terminal units were released to free flavan-3-ols.
- peak E appeared to be catechin or epicatechin benzylthioether.
- procyanidin B2 which is dimer consisting of only epicatechin was thiolysed
- epicatechin and epicatechin benzylthioether as thiolysate were detected from the reaction mixture. Since the retention time of epicatechin benzylthioether from procyanidin B2 was the same as that of peak E, it was considered that that peak E was epicatechin benzylthioether.
- peak G was [M-H] ⁇ at m/z 697.1385 (predicted formula: C37H30O12S) and its MS/MS was [M-H] ⁇ at m/z 573.0987. Again, the difference therebetween was 124.0398 and likely represented the benzylthio adduct. Thus, peak G was estimated to be a benzylthioether of A-type dimer consisting of catechin and/or epicatechin.
- the formula of B-type procyanidin trimer is C45H38O18 and that of A-type is C45H34O18, this peak was likely a trimer in which A-type and B-type interflavan bonds co-existed.
- Peak D was detected as parent MS [M-H] ⁇ at m/z 985.2009 and a predicted formula was removed from benzylthio adduct to C45H36O18. Peak D was suggested to be an A-B type trimer similar to peak B but with a benzylthio adduct.
- peak F The parental mass of peak F was [M-H] ⁇ at m/z 605.1449 and its MS/MS was [M-H] ⁇ at m/z 481.1109, so that a benzylthio adduct was also present in peak F.
- the predicted formula could not be obtained from the parental mass. Since the predicted formula of peak F was undefined, peak F is indicated as “unknown” in TABLE 3.
- the thiolysates of PAC from blueberry leaves were obtained free AB-type trimer, benzylthio adducts of AB-type trimer and A-type dimer other than flavan-3-ol monomer and flavan-3-ol benzylthioether. Since the constitution ratio of flavan-3-ol oligomer and their benzylthio adducts were high relatively, a calculating formula of mDP was modified.
- mDP The mean degree of polymerization
- HCV inhibitor PAC from blueberry leaves (LC3) is summarized in TABLE 3.
- the mDP of PAC in this fraction was estimated to be 7.7.
- the PAC from LC3 fraction was composed of primarily epicatechin, which was 65.1% and 58.1% in terminal units and extension respectively.
- the monomer composition of the A-type dimer and the AB-type trimer were unknown. Therefore, when flavan-3-ol monomer proportion was re-calculated only in detected monomers, 95% of the PAC from LC3 was composed of epicatechin.
- PAC proanthocyanidin
- the crude methanol extract (approx. 500 mg) was then dissolved in 60% methanol and placed on a Sephadex LH-20 column (50 mm ⁇ 50 mm; GE Healthcare). In fractionation, the following series of solvents was used: 400 ml of 60% methanol; 400 ml of 100% methanol; 400 ml of 70% acetone. Each eluent were concentrated by evaporator and lyophilized, finally resulting in approximately 100 mg of solid PAC.
- Sample 2 3 and 9 was prepared directly from raw material and Sample 4 to 8 and 10 was prepared from purchased materials containing PAC. All materials were extracted with 100% methanol, and concentrated by evaporator and lyophilized. Then each PAC preparations were processed by the same method aforementioned using Sephadex LH-20.
- Table 6 shows the HCV replication suppressive activity, PAC contents and the compositions of propelargonidin (PP), procyanidin (PC) and prodelphinidin (PD) which were calculated from results of thiolysis. In the samples showing no PAC contents value of table 6, there were detected little quantity of the yielding PAC.
- the mDP value of PAC preparations from blueberries was around 12 and their composition had epicatechin-rich structure and A-type of interflavan bond.
- the mDP of PAC from taro peel was 10.5 and the most of them were epicatechin and possessed A-type bond.
- mDP was approximately 6.5, and epicatechin was high in composition ratio of extension units, but it was high catechin in that of terminal units.
- the gravinol (Sample 5) was characterized by that the mDP value had relatively-long about 14.4, and the composition ratio of epicatechin-gallate was high in comparison with others.
- the mDP value of the applephenon (Sample 6) was approx. 4.4, same long as that of strawberry (Sample 8).
- both samples (Sample 6 and 8) possessed high ratio of epicatechin composition, but epiafzelechin content was approximately 10% detected only in the strawberry (sample 8).
- the mDP of the cranberry fruit (Sample 7) and the peanut peel (Sample 9) were 6.6 and 7.4 respectively, and both samples had comparatively high ratio of A-type interflavan bond.
- the croton sap (Sample 10) was characterized in that the mDP value was 8.3 and the composition ratio of epicatechin was high, but gallocatechin and epigallocatechin were detected only in the PAC from the croton sap (sample 10), and the ratio became to 37.4% when gallocatechins were converted into prodelphinidin.
- the IC50 value of sample 1 to 9 were less than 1.0 ⁇ g/ml, and the ratio was more than 10. It leads to the conclusion in which these samples could be evaluated to have the suppressive activity on HCV replication. But, in case of the croton sap (sample 10), the IC50 was more than 1.0 ⁇ g/ml, and the ratio of that was less than 10, so that this was evaluated to have no activity.
- freeze-dried powder (105 g) was extracted with 1.2 liters of acetone for 10 min and the supernatant obtained was then decanted. This procedure was repeated five times to remove the green pigment from the leaves, followed by washing in 1.2 liters of hexane for 10 min. The remaining residues were washed with ethyl acetate. The washed powder of leaves was further extracted with 1.2 liters of methanol for 30 min, and the supernatant obtained was then filtered. This procedure was repeated four times and the resulting crude methanol extracts were concentrated by rotary evaporator at 50° C. and lyophilized, finally resulting in approximately 30 g of solid powder.
- PAC with different mDP from blueberry leaves was assessed for the inhibitory activity of HCV replication.
- the HCV replication suppressive activity of PAC from blueberry leaves was clearly dependent on polymerization degree level and the apex activity was observed at a polymerization degree level of around 8 to 9.
- mDP of PAC was preferably at least 5.
- the IC50 value of Sample 10 is more than 1.0 ⁇ g/ml and the ratio is less than 10, so that it is not able to use as anti-HCV agent.
- the degree of polymerization is more than or equal to 3, and delphinidin content was low, so that HCV replication inhibition activity became strong, namely it is useful as anti-HCV agent.
- the HCV production suppressant of this invention possesses the superior anti-HCV effect, so that it is applied to therapeutic medicine or dietary supplements of hepatic disorders from HCV, instead of the interferon therapy.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Pyrane Compounds (AREA)
Abstract
-
- wherein R1 is hydrogen or hydroxyl, R2 is hydroxyl, R3 is hydrogen when R1 is either hydrogen or hydroxyl, but R3 is possibly hydroxyl when R1 is either hydrogen or hydroxyl to the extent that both R1 and R3 being hydroxyl is at most 40 percents in the proanthocyanidin polymer composition
- said units of flavan-3-ol being bonded each other in any one of three patterns as follows;
- (i) a bond between carbon at the position 4 and carbon at the position 8,
- (ii) a bond between carbon at the position 4 and carbon at the position 6,
- (iii) a bond between carbon at the position 4 and carbon at the position 8, and between carbon at the position 2 and oxygen at the position 7.
Description
- 1. Field of the Invention
- This invention relates to an agent for inhibiting production of hepatitis C virus. In particular, this invention also relates to use of proanthocyanidin.
- 2. Related Background Art
- Hepatitis C virus (hereinafter referred to as HCV) has been found as a major causal virus of non-A non-B hepatic inflammation after blood transfusion. HCV is a single-strand RNA virus having an envelope and belongs to Hepacivirus of Flaviviridae.
- In some cases, HCV carriers progress directly to chronic hepatitis without acute hepatitis and then to cirrhosis after many years. About 50 percents of HCV carriers go onto the development of hepatocellular carcinoma. It is said that main cause of such development is persistent infection with HCV. The persistent infection tends to occur even in adults who were infected with HCV after establishing immune system. Even in case of a patient whose site or sites of hepatocellular carcinoma has been completely removed by surgery, the patient still remains at high risk of recurrence, result of the persistent infection repeatedly occurred in unremoved sites.
- Japanese Patent Application Laid-Open No. 2007-119398 disclosed that the process materials of blueberry leaves are effective for inhibiting production of HCV. The publication has, however, no disclosure as to any effective chemical substance contained in blueberry leaves.
- It is reported in Japanese Patent Application Laid-Open No. 2005-239581 that Pycnogenol or proanthocyanidin has anti-virus activities and is useful to improve the quality of life in carriers of HCV. In this publication, the target virus effective of Pycnogenol is myocarditis virus, but it is not HCV. The inhibition of HCV production, which is unlike myocarditis virus, is not able to evaluate by any model animal except chimpanzee. In view of this, there is no explicit description in the publication about the inhibition of HCV production by proanthocyanidin.
- WO2004/047847 refers to an antiviral action of proanthocyanidin and suggests that the proanthocyanidin might be usable for treating hepatic inflammation. Nevertheless, the antiviral action in the publication is against West Nile virus of Flaviviridae. Although HCV belongs to same family, it differs from the West Nile virus in taxonomic genus and the site of infection. The publication has no suggestion as to inhibitory activity of proanthocyanidin for production of HCV.
- U.S. Pat. No. 5,211,944 disclosed that a proanthocyanidin polymer composition having 2 to 11 flavonoid units is specifically useful for treating respiratory virus infection such as respiratory syncytial virus, influenza virus and parainfluenza virus infection, but the respiratory virus is quite different from HCV. So, the publication dose not drop any hint about possible activity of proanthocyanidin against HCV production.
- These days, the interferon therapy is only effective method for inhibiting production or proliferation of HCV, or eliminating HCV. Even so, around 50 percents of the HCV carriers still remain at risk for onset of hepatocellular carcinoma due to failure to clean HCV completely. It is also suggested that interferon should be administered together with ribavirin to enhance disappearance rate of HCV. Further, continuous dosing of interferon in a low dose has been introduced to inhibit progress of hepatitis C disease and then to retard eventually the onset of hepatocellular carcinoma.
- In each case, it is unavoidable to leave some patients who cannot receive the continuous interferon therapy for a long period, because of its strong side-effects such as dehairing, decreased appetite, thrombopenia, depression of white blood cell and so on (See; Shiro Iino, Medical Digest, vol. 46, no. 6, pp. 19-22, 1997).
- An object of this invention is to provide an agent for effectively inhibiting production of HCV with fewer side-effects.
- Another object of this invention is to provide an agent for inhibiting onset, progress and treating of hepatic disease arisen from HCV.
- Further object of this invention is to provide dietary supplements for inhibiting onset or progress of hepatic disease arisen from HCV.
- We, inventors had already found that blueberry leaves have strong suppressive activity against production or proliferation of HCV (See; Japanese Patent Application Laid-Open No. 2007-119398). At that time, it was unclear what effective chemical substance contained in blueberry leaf is. As a result of continuing research on this matter, we have successfully identified that the proanthocyanidin polymer composition with specific chemical formula contained in blueberry leaves has the strong inhibitory activity of HCV production. And then such a finding has led us to this invention.
- An aspect of this invention resides in an agent for inhibiting production of HCV comprising a proanthocyanidin polymer composition. The proanthocyanidin polymer composition has a structure in which flavan-3-ols illustrated in the general formula (1) are bound each other through any of the bond pattern (i), (ii) and (iii) mentioned below. Among the general formula (1), the proportion of flavan-3-ol in which both R1 and R3 are hydroxyl is at most 40 percents.
- (i) the bond between carbon at the
position 4 and carbon at theposition 8
(ii) the bond between carbon at theposition 4 and carbon at theposition 6
(iii) the bond between carbon at theposition 4 and carbon at theposition 8, and carbon at theposition 2 and oxygen at theposition 7 - In the formula (1), R1 is hydrogen or hydroxyl, R2 is hydroxyl, R3 is hydrogen when R1 is either hydrogen or hydroxyl, but R3 is possibly hydroxyl when R1 is either hydrogen or hydroxyl to the extent that both R1 and R3 being hydroxyl is at most 40 percents in the proanthocyanidin polymer composition, and R4 is hydrogen or a univalent organic acid group.
- In this invention, the agent for inhibiting HCV production comprising the proanthocyanidin with the structure aforementioned has advantages of fewer side-effects, dosing over a long period of time and effective anti-HCV production activity.
- In the agent containing proanthocyanidin, R4 in the general formula (1) is preferably a gallate group allowed to have substituent groups.
- Further, in the HCV production inhibitor of this invention, the ratio of the concentration of proanthocyanidin polymer composition inhibiting 50 percents of HCV virus proliferation (IC50) divided by the concentration of proanthocyanidin polymer composition inhibiting 50 percents of cell proliferation (CC50) is desirably at most one tenth. Such an inhibiting agent of HCV production has fewer side-effects and can be dosed for a long period of time.
- The HCV production inhibitor of this invention has the structure in which proanthocyanidin polymer composition has preferably flavan-3-ol unit of the general formula (1) bound each other in any one of the bond pattern (i), (ii) or (iii).
- Another aspect of this invention resides in an agent or a prodrug for treating the hepatic disease arisen from HCV.
- Another aspect of this invention resides in an agent or a prodrug for inhibiting onset or progress of the hepatic disease arisen from HCV.
- Further aspect of this invention resides in a dietary supplement including food or drink for inhibiting onset, progress or treating of the hepatic disease arisen from HCV.
- According to this invention, the agent for inhibiting production of HCV has advantages of significant anti-HCV activities with fewer side-effects and a long dosing period of time.
- The inhibiting agent of HCV production comprising the proanthocyanidin has less cytotoxicity in addition to higher anti-HCV replicon proliferation in vitro. It is, therefore, useful for alternative medicines or dietary supplements instead of interferon. The agent has also advantages to be able to dose continuously for a longer period of time, owing to fewer side-effects compared with interferon. In case of the patients having cirrhosis or hepatocellular carcinoma, numbers of platelets or leucocytes are so small that they would be unable to receive continuously the interferon therapy. The therapy using the agent of this invention can, therefore, become an effective alternative therapy for interferon. The proanthocyanidin is useful for a functional dietary supplement including food or drink as well.
-
FIG. 1 shows HCV replication suppressive activity of PAC from blueberry leaves in replicon cells. -
FIG. 2A shows HPLC chromatogram of methanol extract from blueberry leaves. -
FIG. 2B shows the replication suppressive activity of fractionation by HPLC according toFIG. 2A . -
FIG. 3A shows HPLC chromatogram of 1st fractionation (LC1) of methanol extract from blueberry leaves. -
FIG. 3B shows the replication suppressive activity of LC1 by HPLC according toFIG. 3A . -
FIG. 4A shows HPLC chromatogram of 2nd fractionation (LC2) of LC1. -
FIG. 4B shows the replication suppressive activity of LC2 by HPLC according toFIG. 4A . -
FIG. 5A shows HPLC chromatogram of 3rd fractionation (LC3) of LC2. -
FIG. 5B shows the replication suppressive activity of LC3 by HPLC according toFIG. 5A . -
FIG. 6 shows elemental composition analysis of LC3 (purified fraction from blueberry leaves) by electron probe micro-analysis (EPMA) -
FIG. 7 shows mass spectrum of LC3 (purified fraction from blueberry leaves) by LC/APCI-MS-IT-TOF -
FIG. 8A shows MS/MS spectrum of cyanidin preparation by LC/ESI-MS. -
FIG. 8A shows MS/MS spectrum of LC3 (purified fraction from blueberry leaves) by LC/ESI-MS. -
FIG. 9 shows thiolysis reaction pattern of PAC reacted with benzylmercaptan under acidic condition. -
FIG. 10 shows reverse-phased HPLC chromatogram of thiolysate from LC3 (purified fraction from blueberry leaves). -
FIG. 11 shows the relationship with mean degree of polymerization (mDP) and specific activity (1/IC50) of Sephadex LH-20 fractionation from blueberry leaves. - Referring to the drawings according to need, the preferred embodiments of this invention are described in detail, but does not limit this invention in scope.
- The inhibitory agent for production of HCV in this invention comprises a proanthocyanidin polymer composition (herein after referred to as PAC).
- The PAC in this invention is a polymer composition of matter wherein the monomer unit in the general formula (1) is combined each other in three bond patterns below. The number of monomer unit defining the polymerization degree of PAC is at least 3, preferably at least 5, more preferably 5 to 10. The typical bond patterns of the monomer unit are described bellow.
- (i) the bond between carbon at the
position 4 and carbon at theposition 6
(ii) the bond between carbon at theposition 4 and carbon at theposition 8
(iii) the bond between carbon at theposition 4 and carbon at theposition 6, and carbon at theposition 2 and oxygen at theposition 7 - General Formula (1);
- In this formula (1), R1 is hydrogen or hydroxyl, R2 is hydroxyl, R3 is hydrogen when R1 is either hydrogen or hydroxyl, but R3 is possibly hydroxyl when R1 is either hydrogen or hydroxyl to the extent that both R1 and R3 being hydroxyl is at most 40 percents in the proanthocyanidin polymer composition, and R4 is hydrogen or a univalent organic group respectively.
- As the univalent organic group at the position R4, there can be listed a gallate group, an organic acid residue, and a sugar residue. The organic acid may be p-coumarin acid, caffeic acid, ferulic acid, sinapic acid, p-hydroxyl benzoic acid, gallic acid, acetic acid, oxalic acid, malonic acid, succinic acid, malic acid and so on.
- R4 may also be glycoside residue in which sugars are bound with organic acid residue or gallate groups. The sugars are bound with a phenolic hydroxyl of the gallate groups or the organic acid groups through ester bonds at any position. For instance, there are hexose residues of pyranose type and pentose residues of furanose type. The sugars may be monosaccharide including glucose, galactose, rhamnose, xylose and arabinose, and either disaccharide or trisaccharide.
- Among them, R4 is preferably a gallate group permitted to have substituent groups consisting of a gallate group or a gallate group with substituent. The gallate group with substituent includes a gallate group with which sugar are bound.
- Further, each hydroxyl of A-ring at the
position 5 and/or theposition 7 may be replaced by modified groups such as a gallate group, sugar, organic acid and the like. - Among all flavan-3-ol units forming the PAC polymer composition, the proportion of flavan-3-ol of which both R1 and R3 are hydroxyl is at most 40 percents. In case the proportion is more than 40 percents, it is insufficient to suppress production of HCV. The proportion can be measured by thiol cleavage method.
- For example, one of the PAC of this invention cab be illustrated in the general formula (2), wherein flavan-3-ol units are bound each other at the bond pattern (i).
- Further, there may be a PAC illustrated in the general formula (3), wherein flavan-3-ol units are bound each other at the bond pattern (iii).
- In the general formula (1), R1 and R3 are hydrogen or hydroxyl, R2 is hydroxyl, R4 is oxygen or a univalent organic group, provided that the proportion of both R1 and R3 being hydroxyl is at most 40 percents. Only such a PAC polymer composition can express suppressive activity of the HCV replication in this invention. While the PAC polymer composition wherein the proportion of both R1 and R3 being hydroxyl is more than 40 percents cannot meet the criterion level of the suppressive activity of HCV replication in this invention.
- Although the
position 5 and/or 7 of A-ring in the monomer unit of the general formula (1) is hydroxyl, at least one of them may be a univalent modified group bound therewith. Typical modified groups may be a gallate group, sugar or organic acid. - In this invention, the anti-HCV production activity is actually an activity for inhibiting the replication of HCV replicon cell in vitro, and can be expressed as anti-HCV production activity value (IC50; μg/ml) or the ratio between the anti-HCV production activity value (IC50; μg/ml) and the cytotoxicity value (CC50; μg/ml). It is desirable that the anti-HCV production activity value (IC50; μg/ml) is at most 1.0; μg/ml in terms of the IC50 of interferon. While the ratio of cytotoxicity activity value (CC50; μg/ml) divided by anti-HCV production activity value (IC50; μg/ml) is at least 10 in terms of effectiveness as medicine (See; Naoya Sakamoto et al. Japan clinic, vol. 62, p. 116-120, 2004). The effect of PAC in this invention can be evaluated with the ratio.
- PAC is a kind of the condensed tannin contained in various plants, and can be treated by acids to give cyanidin, delphinidin, pelargonidin, aurantinidin, luteolinidin, peonidin, malvidin, petunidin, europinidin, rosinidin, hirsutidin, apigeninidin and so on. As illustrated in the general formula (1) and (4), the PAC belongs mainly to catechin class, namely, polyphenol groups consisting of condensation polymer, of which polymerization degree of the flavan-3-ol units is at least 2. In these general formulas, R corresponds to OR4 set forth above. Further, a gallic acid is often bound with hydroxyl at the
position 3 of flavan-ring through an ester-link. In other words, PAC can be said to be a generic term including various compositions of matter formed by polymerization of the flavan unit which has hydroxyl at some binding positions. Among the units constituting the polymer, the rear anchor is referred to as ‘terminal unit’ and the other units ‘extension unit’. A polymerization degree of the units extends over the wide range from dimmer to polymers having 100 units or more. - Some polymers in which specified monomer is polymerized are called trivial names. The typical trivial names defined or classified depending on numbers of hydroxyl in B-ring of the flavan units are properalgonidin (4′-OH), procyanidin (3′-OH, 4-OH) or prodelphinidin (3′-OH, 4′-OH, 5′-OH). In addition, there are proguibourtinidin, profisetinidin and prorobinetinidin, all of which has no hydroxyl at
position 5 of A-ring of the flavan units. Depending on whether hydroxyl would be at the specific binding position of flavan units, there are given such a trivial name as proteracacidin, promelacacidin, proluteolinidin and so on. - In this invention, the PAC comprises proanthocyanidin, properalgonidin and/or prodelphinidin. The constituent units of procyanidin may be either one or more of same or different groups, and at least one selected from the group consisting of catechin, epicatechin, catechin gallate and epicatechin gallate. The constituent units of prodelphinidin can also be either one or more of same or different groups, and at least one selected from the group consisting of gallocatechin, epigallocatechin, gallocatechin gallate and epigarocatechin gallate.
- In case R4 of the PAC in the general formula (1) is residues of the univalent organic acid, such as a gallate group, residue of sugar, residue of organic acid, wherein term ‘residue’ means a univalent group or groups caused by losing atom or group in the molecular. As the organic acid in the organic acid residues, there are p-coumaric acid, caffeic acid, ferulic acid, sinapic acid, p-hydroxyl benzoic acid, gallic acid, acetic acid, oxalic acid, malonic acid, succinic acid, and malic acid and so on.
- Sugar in the sugar residue may be bound with the hydroxyl of phenol in any binding position thereof through an ester bond to modify. For instance, the residues constituting glycoside may be hexose residue of pyranose form and pentose residue of furanose form. As concrete example of form of saccharide, there is monosaccharide including glucose, galactose, rhamnose, xylose, arabinose etc., and other disaccharide or trisaccharide.
- The main binding positions among units constituting the PAC are (i) (ii) or (iii) set forth above. As practical embodiment, there are A-type bond consisting of both the bond of carbons at the
position position 2 and oxygen at theposition 7, and B-type bond consisting of either the bond of carbons at theposition position - The PAC as illustrated in the general formula (3) and (4) has A-type bond and B-type bond. According to the findings of the inventors, however, the difference in the extension of A-type bond and B-type bond, or the mixture ratio therebetween does not affect the anti-HCV production activity of the PAC. In the PAC extracted from blueberry, both of the polymerization degree and the proportion of hydroxyl in B-ring in the PAC polymer composition must meet the criterion of this invention, though the B-type bond is dominant.
- According to the differences in binding positions on the rings, there are various PAC polymer compositions, such as steric conformation of substituent groups in flavan unit and binding order among a variety of flavan units. The chemical names of the PAC in this invention are listed as follows. The letters in parentheses express chemical formula. This invention may encompass PACs of higher polymerization degrees, which are polycondensated with constituent units such as catechin and epicatechin, or with other proanthocyanidin.
- Proanthocyanidin PZ 5 (C75H62O31)
- Proanthocyanidin BP 1 (Unspecified)
- Proanthocyanidin RP 4 (C129H106O67)
- Proanthocyanidin RP 3 (C136H120O70)
- Proanthocyanidin CS 4 (C136H120O70)
- Proanthocyanidin CS 3 (C127H128O69)
- Proanthocyanidin CS 2 (C113H110O62)
- Proanthocyanidin CS 1 (C121H118O65)
- Proanthocyanidin RP 2 (C120H114O64)
- Proanthocyanidin RP 1 (C125H130O69)
- Proanthocyanidin T 4 (C128H122O65)
- Proanthocyanidin T 3 (C105H102O59)
- Proanthocyanidin T 2 (C67H54O29)
- Proanthocyanidin T 1 (C87H72O43)
- Proanthocyanidin C 1 (C45H38O18)
- In this invention, the mean polymerization degree of the PAC is preferably at least 5 in terms of anti-HCV production activity as shown in
FIG. 11 . However, if a PAC polymer composition contains at least 3 of monomer unit of the general formula (1) in the mean polymerization degree; its anti-HCV replicon production activity value is at most 1.0 μg/ml; the ratio of cytotoxicity activity value (CC50) divided by anti-HCV production activity value (IC50) is at least 10, such PAC polymer compositions are covered in this invention. - In this invention, the mean polymerization degree of the PAC means the average number of flavan-3-ol units bound each other with the bond pattern (i), (ii) and (iii). The number of flavan units can be determined by the method described in the example 1.
- The PAC may be either synthetic product or natural product. The natural product can be derived from some plants containing polyphenol. It is known that some colored fruits and vegetables are high content of polyphenol. There can be illustrated by examples of blueberry leaves, grape seeds, taro, bilberry, elderberry, plum, blackberry, strawberry, redcurrant, blackcurrant, cranberry, cherry, raspberry, currant, a hibiscus flower, green pepper, beans, peas, soybean skin, a red cabbage, a purple corn, a purple sweet potato, herbs, fern, nuts, bark etc. Particularly, the blueberry leaves, the grape seeds and taro are very effective for the inhibitory activity of HCV production. The skin of Taro contains a large amount of proanthocyanidin. It may be practical to use the skin of Taro, in spite of the unsuitable part for eating.
- Various parts of a plant or its processed good are also useful for the starting material of this invention. The usable starting material is, for example, leaves, petals, calyx, flowers, leafstalks, fresh tops, roots, stems, seeds, pods, rhizomes, barks, cambiums, lumbers, mycocecidium, fruits, tree saps, resin, a peel of grape, apple, onion, avocado and citrus; pomas of apple, wine, grain hull, straw and hay; the lumps from oily seeds derived from olive, oilseed rape and canola; and the extracts from other oily crops etc.
- The most preferable starting material is blueberry shown in the example 1. The blueberry belonging to Cyanococcus of Vaccinium of Ericaceae is a deciduous or evergreen fruit tree, which is a low tree or a low bushes originally comes from America. The Usable blueberries in this invention are without reference to kinds and native localities thereof and are limited to the listed above. The blueberry is generally classified into around six kinds, among which the routine use of horticulture is said to be three kinds below.
- (1) Highbush blueberry (Vaccinium corymbosum L.); O'Mear, sharpblue, Flordablue, Reveille, Spartan, Darrow, Duke, Berkeley, Harrison etc.
- (2) Rabbiteye blueberry (V. Firgatum Aiton); Woodard, Garden blue, Tifblue, Homebell, Myers etc.
- (3) Lowbush blueberry (V. angustifolium Aiton, V. myrtilloides Michaux); Chignecto, Brunswick, Blomidon etc.
- Rabbiteye blueberry is most useful staring material among them listed above.
- The PAC as effective ingredient in this invention can be produced by combination of following steps depending on intended use. (1) Pretreatment step: First of all, blueberry leaves are washed with water and filtered to remove unusable miscellaneous things therefrom. The unwanted components such as cellulose, chlorophyll etc. in the crude material after washing are distilled away with organic solvent. As the organic solvent, chloroform, hexane, acetone etc. and the combination thereof can be properly used. The distillate may be supplied to next step directly or after pulverizing with or without drying. Extracted or squeezed juice from the crude material can also be supplied as well. Before supplying next step, the extracted or squeezed juice may be condensed, dried and pulverized into powder.
- Any conventional dryer can be used in this invention, so long as changing nature of chemicals in the crude material. For instance, a vacuum-freeze dryer, a hot air dryer, a far-infrared radiation dryer, a reduced-pressure dryer, a micro-wave reduced-pressure dryer, a super-heated steam dryer etc. can be used. Among them, the vacuum-freeze dryer is more useful, because of having few effects on the nature of the chemicals. The Vacuum-freeze dryer should be used under the designated condition depending on the state of leaves to be processed. For example, in case of fresh leaves, it is desirable that freezing temperature is from −30 to −20° C.; drying temperature from −30 to 30° C.; and drying
period 15 to 24 hours. - (2) Extract step: The processed material in the former steps is then extracted with a solvent or solvents through single or multiple steps. In the extract process, the solvents may be used either alone or the combination thereof. For example, water or polar solvent compatible with water can be preferably used. As the solvent compatible with water, there are lower alkyl alcohol with numbers of
carbon 1 to 4, such as methanol, ethanol, propanol, butanol etc. and polyol such as ethylene glycol, butylene glycol, propylene glycol, glycerin etc. Among them, lower alkyl alcohol such as methanol or ethanol may be practical in terms of safety. - Other organic solvent, such as acetone, diethyl ether, dioxane, acetonitrile, ethyl acetate, xylene, chloroform, toluene, hexane etc. can also be used. These solvents may be used in either single or the combination thereof, such as the combination of water and polar solvent compatible with water. For instance, the mixed solvent of acetone and ethyl ether can be used preferably in the ratio of 1:1 by v/v. It is general to use the mixture of water and polar solvent as the mixed aqueous solvent. As aqueous alkyl alcohol, aqueous methanol and ethanol may be preferably used. The alcohol content in the aqueous alcohol is in the range of 5 to 90 percents, preferably 30 to 90 percents, more preferably 50 to 90 percents. It is recommended to use mixed alcohol solvent containing water or acetone in this invention.
- In the extraction process, the processed material in above steps is immersed in cool or warm solvent. It is usually extracted under warming and agitating and then filtrated to give extracted liquid. For example, the extraction may be preferably carried out using an aqueous alcohol solvent containing 80 volume percents of alcohol at room temperature and for immersion periods of 30 to 60 minutes depending on the extracting temperature. The extraction can be done by percolation method too.
- (3) Purification step: The impure solid materials can be removed from the obtained extract by filtration or centrifugal separation to give pure filtrate, if needed. The filtrate may be supplied to the next step directly, or after partially condensed by distillation or dried. Further, these condensed or dried materials can be further purified by the method such as column method or fractionation method with solvent (See; WO2000-64883).
- Taro (Colocasia esculenta Schott) usable in this invention as one of the material of the PAC belongs to Colocasia, Araceae, originated from the South Asia and is widely cultivated in the many varieties over the world. The root stocks and leaf stems have been mainly utilized for foodstuffs so far. Among araceae, there is konjac (Amorphophallus konjac), which can be used as foodstuff after processing. In addition, there are several varieties in araceae for appreciation too. It is known that the root stock of Araceae plants contains mucin, galactan and potassium as effective ingredients. It is also reported that galactan has activity of brain cell and immunity. Potassium prevents high blood pressure due to removing sodium. But there have been no report on anti-HCV production activity of the root stock of Araceae plants until now.
- The root stocks of Araceae plant are generally used after processing in this invention to realize effective anti-HCV production. As typical processing method of the root stocks, there are pulverization, dried pulverization, squeezation and solvent extraction.
- In general, the root stocks are pulverized after drying or slicing before drying. The root stocks of Araceae can be dried according to the drying method of blueberry leaves set forth above. The extraction process and purification process can also be carried out by the same way as blueberry leaves.
- The PAC in this invention can be prepared into various formulations such as extracted solution, condensed solution, paste, and dried or semidried powder. The purified PAC is understandably higher anti-HVC production activity compared with crude extracts.
- There is no appropriate evaluation system for anti-HCV production activity in vivo except chimera mouse, because HCV dose not infect all animals other than primates. In this invention, HCV replicon cell as known in vitro evaluation system of HCV replication (Lohmann V. et al., Science Vol. 285, p. 110-113, (1999)) is employed as alternative vivo evaluation method. HCV replicon cell comprises a structural protein translation region with core and envelop constituting virus particle, and non-structural protein translation region having function of virus genome replication etc. The HCV replicon cell may be made from the non-structural region. The replication of HCV-RNA in this system is measured as replication numbers of whole HCV-RNA infected with HCV.
- The effective mean degree of polymerization (mDP) of the flavan unit in general formula (1) is at least 3 in integer value. As shown in table 1, no anti-HCV production activity is found in catechin (DP=1) and catechin dimmer (DP=2). These findings suggest that other epicatechin, afzelechin and epiafzelechin would be few activity of anti-HCV production too.
-
TABLE 1 The activity of inhibiting replicon production HCV Replication Suppressive Activity of Catechin Monomer and Epicatechin Dimer Replication suppressive Cytotoxicity Ratio activity IC50(μg/ml) CC50(μg/ml) CC50/IC50 Catechin 16.18 100.4 6.2 Epicatechin 27.32 113.8 4.2 Procyanidin B2 >25.0 >25.0 — - This invention encompasses PAC polymer composition wherein the position R2 of flavan unit in the general formula (1) is hydroxyl; the position R1 and the position R3 are hydrogen or hydroxyl; and the position R4 is hydrogen or modified groups, so far as the proportion of both R1 and R3 being hydroxyl is at most 40 percents of whole polymer composition. The anti-HCV production activity of gallocatechin and epigallocatechin so called generally prodelphinidin wherein all the position R1, R2 and R3 in B-ring of the flavan unit are hydroxyl is likely quantity dependant inverse proportion as illustrated in the table 2. For instance, in case the proportion of the flavan units such as croton sap exceeds 40 percents of whole polymer composition, such polymer composition becomes stronger in cytotoxicity and less than or equivalent to 10 in the ratio between IC50 and CC50 as shown in the table 3 of the example 1. Accordingly, the polymer composition is unusable in practice as the inhibitor of HCV production in this invention.
- The PAC of this invention may be produced chemically or biologically. The PAC is also purified directly from the natural material such as plants, provided that its structure and function fall within the scope defined in this invention.
- The PAC may be supplied to end users in various formulations such as extracted solution, condensed solution, and dried or semidried powder etc. depending on their request.
- The inhibitory agents of HCV production in this invention may be available directly, or as either prodrug or formulated medicine. The PAC may be administered to persons infected with HCV, in the form of either polymer composition alone as shown in the general formula (1), or together with medically acceptable salts, hydrates and solvates. In general, it seems to be rather effective to dose a drug comprising the PAC and pharmacologically and pharmaceutically acceptable additives.
- As the pharmacologically and pharmaceutically acceptable additives, there may be diluent, disintegrant, auxiliary disintegrant, binder, lubricant, coating, pigment, base agent, solvent, auxiliary solvent, isotonic agent, pH regulator, stabilizer, injection agent, adhesive and so on.
- When using the PAC as a drug, it is desirable to administrate in every dosing unit. As such dosing manner, there are oral administration, enteral administration, intravenous administration, local administration such as dermal administration, and interstitial administration such as subcutaneous administration, intramuscular administration etc.
- As solid dosage formulation for oral administration, there may be tablet, ball, capsule, subtle granule or pill. In addition, there may be acceptable emulsion, suspension, and syrups as liquid dosage formulation for oral administration. When formulating drugs, lubricant, colorant, flavoring agent, and/or pH regulator can be added to the base agent including the PAC. The tablet may be coated with conventional sugar coating, gelatin coating, enteric coating tablet, film coating, double coating and multiple coating, if required. As the additives, there may be used diluents such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, hydrated silica etc.; binders such as water, ethanol, propanol, sirup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinyl pyrolidone etc.; disintegrants such as dried starch, sodium argininate, agar powder, laminarin powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose etc.; disintegrant suppressing agent such as sucrose, stearin, cacao butter, hydrogenated oil etc.; adsorption promoter such as quaternary ammonium salts, sodium lauryl sulfate etc.; humectants such as glycerin, starch etc.; absorbents such as starch, lactose, kaolin, bentonite, colloidal hydrated silica etc.; and lubricants such as purified talc, stearate, boric acid powder etc.
- As the enteral administration, there may be the use of injectable products. When preparing the injectable products, it can be made in formulation of nontoxic solution, suspension or emulsion preferably sterilized and adjusted to the isotonicity nearly equal to blood. These suspension and emulsion can be prepared by using water; ethanol, propylene glycol, ethoxyisostearyl alcohol, polyoxyisosteayl alcohol etc; and/or polyoxyethylene sorbitan fatty acid ester. Further, there can be added sufficient amounts of salt, glucose and/or glycerin etc so as to obtain isotonic solution. In addition, usual solubilizing agents, buffering agents, pH regulating agents, soothing agents and the like can also be used. The injectable product can be administered under skin, into muscle or vein.
- For local administration, there may be topical solution, cream, powder, paste, gellant and ointment. These are prepared by combining a given quantity of the effective ingredients including the PAC, and its pharmacologically and pharmaceutically acceptable prodrug or salts, together with additive usable for topical medicine such as fragrance, colorant, filler, surfactant, humectant, emollient, gellant, carrier, preserving agent and/or stabilizer.
- For the formulation of interstitial administration, a suppository is typical. When preparing the suppository, there can be used higher alcohol; higher ester such as myristicin palmitate ester, polyethylene glycol, cacao butter, gelatin, semi synthetic glyceride and their mixture as substrates with low melting point. The suppository can be formulated by adding the PAC, its prodrug and their medically acceptable salt to these substrates.
- When ministering the PAC or the inhibitory agent of HCV production containing its prodrug with their medically acceptable salt to patients needed thereof, the effective dosing quantity should be determined in view of condition of each patient of which condition are, for instance, a time of life, weight, the route of administration, the nature or level of disease etc. This invention suggests that the effective dosing quantities may be within the range of 1 to 2000 mg per a day for an adult human. But, according to clinical condition of a patient, the effective dosing quantities may be less than or larger than the suggested range. When dosing larger quantities than the suggested range, it is desirable to dose fractionally at several times per a day. The agent of this invention can also be adopted for preventing or inhibiting onset or progress of hepatic inflammation and cirrhosis, or treating hepatitis diseases arisen from HCV, in addition to the inhibition of HCV production that is the primary activity of this invention.
- In case of pharmaceutical agent, the effective quantity of administration to a patient can not be determined strictly owing to variable dependant on the expected effect of treatment, administration method or its root, dosing periods, gender of a patient, and other condition of disease. Typically, the dosing quantities of the anti-HCV inhibitor including crude or purified production of this invention may be selected from the range about 100 to 1000 mg per a dose for the weight of 60 kg in a human patient as reduced weight of the purified PAC of this invention. The content of the PAC in the agent may be selected from the range of 0.1 to 99.5 weight percents, preferably 0.5 to 90 weight percents, though the content is needed not to specifically limit, because of variable dependant on the dosing quantities. Whenever necessary, the agent of this invention can be dosed. But, it is effective to dose in acute or chronic stage of hepatitis inflammation or stage of cirrhosis during which the state of hepatic disease is in progress.
- Further, the PAC of this invention may be usable for dietary supplements such as food or drink. The supplements can be prepared in solid, liquid solution, emulsion and so on, and shaped into various forms such as tablet, ball, capsule, granule, powder, pastille, cake, drink etc. According to need, pharmacologically, pharmaceutically and dietary acceptable additives can be added. The additives include other various medical substances or functional ingredients such as vitamin, other minor components and the like.
- Following examples illustrate more detail embodiments of this invention without, however, limiting the invention in any way. In the working example, percent (%) means weight percent (w/w %), unless otherwise stated.
- [Experimental Procedure]
- In the working example, the HCV replication suppressive activity test (replicon assay) and cytotoxicity test were carried out as follows.
- The HCV-replicon cell line was established by transducing sub-genomic RNA into human hepatoma Huh-7 cell cytoplasm. The sub-genomic RNA was prepared by replacing the translated region of HCV genome RNA structural proteins with firefly luciferase gene, internal ribosome entry site (IRES) of the encephalomyocarditis virus and neomycin phosphotransferase gene. The cell line obtained was used for assessment of production of HCV replicon RNA. The production quantity of HCV replicon RNA was measured by the luciferase assay method. (Lohmann et al., Science 285, (1999) 110; Sakamoto et al. Nat. Chem. Biol. 1, (2005) 333)
- Anti-Replicon Activity Test (Replicon Assay)
- In order to determine replication quantity of HCV-RNA, luciferase genes from firefly were transduced into HCV-RNA as a reporter gene. The gene transduction was carried out according to the method of Krieger et al. (See; Krieger et al. J. virol. 75, (2001) 4614) in such manner that luciferase genes were fused together neomycin-resistant genes beneath the IRES of HCV gene.
- With this HCV subgenome, the replication efficiency of HCV could be estimated by measuring luciferase activity in the HCV replicon cells. The HCV replicon cells used were routinely grown in DMEM (Gibco cat. No. 10569-010) supplemented with Glutamax (Invitrogen), 10% fetal bovine serum (FBS), 1% penicillin/streptomycin (Invitrogen) and 500 μg/ml G418 (Invitrogen). The cells were maintained at 37° C. in humidified atmosphere containing 5% CO2. For the HCV replication assay, the replicon cells in DMEM supplemented with Glutamax and 5% FBS were seeded in a 96-well plate so as to fill every well with 5000 cells, and incubated for 24 hours.
- The test was carried out in such a way that the HCV replicon cells were cultured for 72 hours after adding test samples in different concentrations. The Quantity of the luciferase activity was determined by the Steady-Glo Luciferase Assay System (Promega) according to the manufacture's instructions and the luminescence was measured by
DTX 800 Multimode Detector (Beckman). In this test, the replication inhibitory activity is expressed as a concentration of samples required for inhibiting 50 percents of the replication of HCV replicon cell (IC50). Specific activity is a reciprocal number of IC50 (1/IC50). Total activity is calculated by multiplying the yield weight of the HCV replicon cell by specific activity. - Cytotoxicity Test
- The cytotoxicity of the samples was measured by Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies) according to the manufacture's instructions. Briefly, 10 μl/a well of CCK-8 reagent were added to the HCV replicon cells cultured in a 96-well plate and then incubated at 37° C. for 60 min. The absorbance of each well was measured at 450 nm with a reference wavelength at 650 nm using an Emax Precision microplate reader (Molecular Devices Inc.). Cell viability was calculated as relative index of control cells and effects of samples and was expressed as the concentration of samples required for 50% cytotoxicity of the cells (CC50).
-
FIG. 1 illustrates the results of a PAC sample from blueberry leaves in replicon assay. The IC50 value showing the replication suppressive activity was 0.56 μg/ml and the CC50 value showing the cytotoxicity was 16.26 μg/ml. The IC50 was less than or equal to 1.0 μg/ml and the ratio, which was calculated by dividing CC50 by IC50, was larger than or equal to 10. In conclusion, the PAC sample has the inhibitory activity of HCV replication. - 1. Extraction and Liquid-Liquid Distribution
- One gram of the lyophilized powder, which made from the leaves of rabbit-eye blueberry (Vaccinium virgatum Aiton), was extracted with 100 ml of methanol at room temperature under shaking for 15 min, and the supernatant of the resultant extract was passed through filter paper (Toyo filter paper No. 2). The methanol extract was further extracted with 100 ml of chloroform, followed by the resultant precipitate and supernatant were collected. The precipitate was dissolved in methanol, concentrated in vacuo and lyophilized (CMW-ppt: 63.7 mg). The supernatant was mixed with 150 ml of distilled water and methanol to perform a liquid-liquid extraction, and the water layer was collected and mixed with 150 ml of chloroform so as to repeat the chloroform extraction. The water layer was concentrated and lyophilized (CMW-W: 284.2 mg). The chloroform layer was also concentrated and lyophilized (CMW-C, 56.3 mg).
- The suppressing activity of HCV replication was not detected from the CMW-C fraction in replicon cell assay, but detected from the CMW-ppt and the CMW-W. In following purification, the CMW-W with a large recovered amount in weight and a large amount of total activity was used.
- 2. The Fractionation by HPLC (Confirmation of Elution Time by HPLC)
- To separate the components in the CMW-W fraction possessing HCV replication inhibitory activity, fractionation and purification were performed using HPLC (Prominence System; Shimadzu) with UV detector and photodiode array detection (PDA). The other analytical condition shows as follows.
- Instrument: Shimadzu Prominence LC-20A
- Column: Atlantis dC18, 4.6 mm I.D.×150 mm, 3 μm (Waters), 40° C.
- Eluent: (A) 0.05% (v/v) Trifluoroacetic acid
-
- (B) Acetonitrile
- Gradient: Eluent B. 15% (0 min)-25% (12.5 min)-100% (17.5 min)-100% (25 min)
- Flow Rate: 0.7 ml/min
- Detector: 254 nm
- 50 μl of the CMW-W fraction dissolved in 30 ml of methanol was injected into HPLC and the eluted total 26 fractions were collected during a period from 2.3 to 19.5 min. The replicon assay of collected each fraction was carried out in concentration of 1%, 5% and 10%.
-
FIGS. 2 (A) and (B) shows HPLC chromatogram and activity of suppressed replication for collected fraction, respectively. The data indicated that a fraction having strong replication inhibitory activity and eluted by around 90% of acetonitrile at 17 min contains some week inhibitory activity fractions same as broadly eluted fraction earlier. Those results suggested the possible existence of multiple replication inhibitors in CMW-W fraction. However, the chlorogenic acid and the rutin included lots in blueberry leaves and eluted at around 6 and 11 min respectively were seem not to have the inhibition activity aforementioned. - (1st Fractionation) the 1st fractionation performed under the following condition.
- Column: Atlantis T3, 4.6 mm I.D.×150 mm, 3 μm (Waters), 40° C.
- Eluent: (A) 0.05% (v/v) Trifluoroacetic acid
-
- (B) Acetonitrile
- Gradient: Eluent B. 30% (0 min)-30% (7.5 min)-100% (12.5 min)-100% (20 min)
- Flow Rate: 0.7 ml/min
- Detector: 254 nm
- 100 μl of the CMW-W fraction was injected into HPLC system and the eluted 26 fractions during from 2.1 to 18 min were collected.
FIG. 3 shows the results of HPLC chromatogram and replicon assay in the collected fractions. - In order to purify the most active component, the CM was separated into isocratic condition at 30% acetonitrile and the eluate from 3.3 to 5.2 min, and then the latter was collected. After repeating collection, 140.2 mg as active fraction (LC1) was obtained from 440 mg of methanol extracts. The IC50 value of this fraction in the HCV replication assay was 0.89 μg/ml and the yield of specific activity was 6-fold higher than that of the initial methanol extracts (TABLE 2).
- (2nd Fractionation) The 2nd fractionation performed under the following condition.
- Column: Atlantis T3, 4.6 mm I.D.×150 mm, 3 μm (Waters), 40° C.
- Eluent: (A) 0.05% (v/v) Trifluoroacetic acid
-
- (B) Acetonitrile
- Gradient: Eluent B. 20% (0 min)-20% (7.5 min)-100% (12.5 min)-100% (20 min)
- Flow Rate: 0.7 ml/min
- Detector: 254 nm
- The active fraction (LC1) of 140.2 mg obtained from 1st fractionation was dissolved in 11 ml of methanol. The solution obtained was injected into HPLC system. The eluted fraction was collected from 2.1 to 18 min (
Total 26 fractions).FIG. 4 shows HPLC chromatogram and replicon assay of collected fractions. - In the second round HPLC, a highly active fraction was eluted from 11.9 to 13.2 min and collected (LC2), yielding 24.6 mg with an IC50 value 0.54 μg/ml (TABLE 2).
- (3rd Fractionation) In the 3rd fractionation, the eluent B was replaced by methanol and eluted with 40-65% B linear gradient under the following condition.
- Column: Atlantis T3, 4.6 mm I.D.×150 mm, 3 μm (Waters), 40° C.
- Eluent: (A) 0.05% (v/v) Trifluoroacetic acid
-
- (B) Methanol
- Gradient: Eluent B. 40% (0 min)-65% (12.5 min)-100% (17.5 min)-100% (25 min)
- Flow Rate: 0.7 ml/min
- Detector: 254 nm
- 24.6 mg of the active fraction (LC2) were dissolved in 2.5 ml of methanol. The LC2 methanol solution was injected into HPLC system. The eluted fraction was collected from 2.3 to 17.5 min (total 26 fractions).
FIG. 5 shows HPLC chromatogram and replicon assay of collected fractions. - The active fraction was eluted during from 3.2 to 6.2 min and collected (LC3). The finally yielded solid material of 2.9 mg had a dark flesh color.
- TABLE 2 shows an overall purification steps from blueberry leaves. From 1000 mg of lyophilized powder of the leaves, 440 mg of methanol extracts were obtained. The IC50 value of methanol extracts was 5.47 μg/ml. From the 284.2 mg of the CMW-W fraction was found out the replication inhibitory activity wherein the IC50 value was 1.74 μg/ml; the specific activity of the CMW-W was 3-fold greater than that of the initial extracts; and the yield of the activity exceeded 200%. These values result from that the interfering substances had been removed from the test sample.
- The final fraction which was purified by repeated fractionation in reversed-phase HPLC showed a 63-fold increase in specific activity compared with the initial methanol extracts. The CC50 value of the cytotoxicity of LC3 was 18.5 μg/ml and the ratio was 212.6 that was a 16.5-fold higher ratio compared with initial extracts.
-
TABLE 2 Purification Steps from Blueberry Leaves Specific Total Activity Total Weight IC50 (1/ Purification Activity Yield (mg) (μg/ml) IC50) Factor (mg/IC50) (%) MeOH 440.0 5.47 0.18 1.00 80.44 100 Extract 284.2 1.74 0.57 3.14 163.33 203.05 Water Layer LC1 140.2 0.89 1.12 6.15 157.53 195.84 LC2 24.6 0.54 1.85 10.13 45.56 56.63 LC3 2.9 0.087 11.49 62.87 33.33 41.44 - 3. The Elemental Composition Analysis of Electron Probe Micro-Analysis (EPMA)
- For EPMA (EPMA-1600, Shimadzu), the excitation voltage and the beam current were kept at 15 kV and at 100 nA, respectively. The diameter of the electron beam was 50 μm and the sample was processed for carbon shadowing in advance. In order to determine the constituent elements, the purified fraction (LC3) was analyzed by EPMA. This analysis indicates that the fraction is composed of carbon, oxygen and hydrogen, but not nitrogen (
FIG. 6 ). - 4. The Constitutive Analysis of Liquid Chromatography/Mass Spectrometry-Ion Trap-Time of Flight (LC/MS-IT-TOF)
- Identification of the anti-HCV replication fraction (LC3) purified from blueberry leaves was done by HPLC-MSn fragmentation analysis. An HPLC (Prominence System; Shimadzu) on a reverse-phase column was equipped with a PDA detector scanning from 200 to 800 nm and mass spectrometry-ion trap-time of flight (MS-IT-TOF; Shimadzu) detector. The instrument and analysis condition show as follows.
- Instrument: Shimadzu LC/MS-IT-TOF
- Column: Atlantis T3, 2.1 mm I.D.×100 mm, 3 μm (Waters), 40° C.
- Eluent: (A) 0.05% (v/v) Trifluoroacetic acid
-
- (B) acetonitrile
- Gradient: Eluent B. 10% (0 min)-25% (7.5 min)-100% (12.5 min)-100% (20 min)
- Flow Rate: 0.25 ml/min
- Detector A: PDA 280 nm
- Detector B: Atmospheric pressure chemical ionization (APCI)-MS (Negative-ion Mode; interface voltage, −3.0 kV, interface temperature, 450° C.; curved desolvation line (CDL) temperature, 200° C.; nebulizer N2 gas, 2.0 L/min; drying N2 pressure, 70 kPa; heat block temperature, 200° C.)
- In the preliminary trials of LC/MS analysis, the electrospray ionization (ESI) was used as ionized probe, but the target compounds were not able to observe in mass spectrum. When exchanging the ionization probe for APCI and setting the interface temperature at 450° C., the mass spectrum of target compounds could be found out.
- The mass spectrum data shows five peaks (
FIG. 7 ). The [M-H]− at m/z 401.0494 and 689.1135 were considered to be trifluoroacetic acid adducts of m/z 287.0553 and 575.1196 respectively. From these spectra, the parent mass of this compound appeared to be [M-H]− at m/z 575.1196, which was estimated to be C30H24O12 (error=0.17 ppm) that is an A-type dimer of procyanidin. Given the fact that strict conditions (APCI probe temperature at 450° C.) were required to ionize the compound, it appeared that the isolate was composed of one or more polymers of procyanidin. - 5. Identification of Proanthocyanidin (PAC) by Butanol-HCl Method (Porter Method)
- PAC were characterized by a modified method of Porter et al. (Porter et al., Phytochem. 25, (1986) 223; Shoji et al., J. Agric. Food Chem. 54, (2006) 884)
- Heating PAC under acidic condition, carbenium ion and catechin are produced by disconnecting the interflavan-bond thereof. The former are more oxidized to give a red anthocyanidin. The porter method based on the principle of these color reaction is able to perceptively detect PAC from samples in increasing absorbance at 540 nm.
- (1) Quantitative Determination and Qualitative Analysis of PAC by Porter Method
- 200 μl of the purified compound from blueberry leaves was mixed with 750 μl of n-butanol/HCl (95:5) and 50 μl of 1% of NH4Fe(SO4)2.12H2O dissolved in 2M HCl. The mixture was vortexed and heated in an oven at 105° C. for 40 min and cooled in flowing water. Optical densities of the treated solution were recorded at 540 nm by spectrophotometer (UV-1700, Shimadzu). Procyanidin B2 (Sigma-Aldrich) was used as a standard.
- (2) LC/MS Analysis of Porter Method Products
- The hydrolysates generated by the modified Porter method were also analyzed using LC/MS-IT-TOF as follows.
- Instrument: Shimadzu LC/MS-IT-TOF
- Column: Atlantis T3, 2.1 mm I.D.×100 mm, 3 μm (Waters), 40
- Eluent: (A) 0.5% (v/v) Formic acid containing 5 mM Ammonium Formate
-
- (B) acetonitrile
- Gradient: Eluent B. 10% (0 min)-40% (15 min)-100% (15 min)-100% (22.5 min)
- Flow Rate: 0.25 ml/min
- Detector A: PDA 540 nm
- Detector B: ESI-MS (Positive-ion Mode; interface voltage, 4.5 kV, interface temperature, 200° C.; curved desolvation line (CDL) temperature, 200° C.; nebulizer N2 gas, 1.5 L/min; drying N2 pressure, 200 kPa; heat block temperature, 200° C.)
- The purified LC3 fraction was analyzed by Porter method. The reacted solution turned a red color, which corresponds to the color of anthocyanidin generated by heating of procyanidin/proanthocyanidin mixture under acidic conditions. Using procyanidin B2 as the standard, the procyanidin content in the LC3 fraction was 86.33%. The hydrolysis solution was analyzed by LC/MS-IT-TOF. The main peak (RT=7.3 min) of the PDA chromatogram at 540 nm was observed at the same position as that of the cyanidin standard (
FIG. 8A ). Indeed, MS/MS spectra of this peak were identical to those of the cyanidin standard (FIG. 8B ). These results revealed that the HCV replication inhibitory compound in the LC3 fraction from blueberry leaves was procyanidin and its derivatives. As the hydrolysate of this compound also contained a trace amount of delphinidin, these compounds was considered to be proanthocyanidin rather than procyanidin. - 6. Analysis of Mean Degree of Polymerization (mDP) and Composition Units for PAC by Thiolysis
- Thiolysis was performed by previously described method with some modifications (Guyot et al., J. Agric. Food Chem. 49, (2001) 14; Gu et al., J. Agric. Food Chem. 50, (2002) 4852). Briefly, 50 μl of PAC samples (2 mg/ml in methanol) was mixed with 50 μl of methanol acidified with HCl (3.3%) and 100 μl of benzylmercaptan (5% in methanol). The reaction was carried out at 50° C. for 30 min and then kept at ambient temperature for 3 hours. Pure catechin or epicatechin solution (1.25 mg/ml in methanol, Funakoshi) was also thiolysed to obtain the epimerization rate by calculating the ratio of catechin and epicatechin in the terminal units. The reaction mixture was diluted 5-fold with methanol and analyzed by reverse-phase HPLC as follows.
- Column: Atlantis T3, 4.6 mm I.D.×150 mm, 3 μm (Waters), 40° C.
- Eluent: (A) 0.05% (v/v) Trifluoroacetic acid
-
- (B) Acetonitrile
- Gradient: Eluent B. 15% (0 min)-25% (10 min)-100% (40 min)-100% (45 min)
- Flow Rate: 0.7 ml/min
- Detector: 280 nm
- To ascertain the elution pattern of thiolysis media and to estimate unknown peaks, LC/MS-IT-TOF was also employed in a negative ion mode. The instrument and analysis condition show as follows.
- Instrument: Shimadzu LC/MS-IT-TOF
- Column: Atlantis T3, 2.1 mm I.D.×100 mm, 3 μm (Waters), 40° C.
- Eluent: (A) 0.05% (v/v) Trifluoroacetic acid
-
- (B) acetonitrile
- Gradient: Eluent B. 15% (0 min)-25% (10 min)-60% (40 min)-100% (40 min)
- Flow Rate: 0.25 ml/min
- Detector A: PDA 280 nm
- Detector B: ESI-MS (Negative-ion Mode; interface voltage, −3.0 kV, interface temperature, 200° C.; curved desolvation line (CDL) temperature, 200° C.; nebulizer N2 gas, 1.5 L/min; drying N2 pressure, 200 kPa; heat block temperature, 200° C.)
- Flavan-3-ols and their benzylthio adducts obtained by thiolysate of procyanidin B2 was used as a standard.
FIG. 9 shows the basic reaction of thiolytic cleavage. In thiolytic reaction, the PAC was reacted with benzylmercaptan under the acidic condition so that the extension units of PAC were released to the corresponding benzylthioether and the terminal units were released to free flavan-3-ols. - As a result that thiolysis products of purified PAC in the LC3 fraction were analyzed in reverse-phased HPLC, several peaks were identified (
FIG. 10 ). The peaks A, C and H were considered to be catechin, epicatechin and benzylmercaptan respectively according to the retention time of each standard preparation. Other peaks were confirmed by analyzing mass spectra. - The parent mass of peak E was [M-H]− at m/z 411.0892, with an estimated formula C22H20O6S (error=−3.8 ppm), and its MS/MS spectrum was [M-H]− at m/z 287.0510. The difference between the parental mass and MS/MS was 124.0382, which corresponded to a benzylthio adduct. Thus, peak E appeared to be catechin or epicatechin benzylthioether. Furthermore, when procyanidin B2 which is dimer consisting of only epicatechin was thiolysed, epicatechin and epicatechin benzylthioether as thiolysate were detected from the reaction mixture. Since the retention time of epicatechin benzylthioether from procyanidin B2 was the same as that of peak E, it was considered that that peak E was epicatechin benzylthioether.
- The parental mass of peak G was [M-H]− at m/z 697.1385 (predicted formula: C37H30O12S) and its MS/MS was [M-H]− at m/z 573.0987. Again, the difference therebetween was 124.0398 and likely represented the benzylthio adduct. Thus, peak G was estimated to be a benzylthioether of A-type dimer consisting of catechin and/or epicatechin.
- According to Thompson et al. (Thompson et al., J. Chem. Soc. Perkin Trans. 1 (1972) 1387), the interflavan linkages in PAC were resistant to thiolysis. After thiolysis, they would be released as free A-type dimmers, if present in the terminal units or as the corresponding benzylthioether, if present in the extension units (Foo et al., J. Nat. Prod. 63 (2000) 1225).
- Peak B was detected as parent MS [M-H]− at m/z 863.1822 with a predicted formula C45H36O18 (error=−0.86 ppm). As the formula of B-type procyanidin trimer is C45H38O18 and that of A-type is C45H34O18, this peak was likely a trimer in which A-type and B-type interflavan bonds co-existed.
- Peak D was detected as parent MS [M-H]− at m/z 985.2009 and a predicted formula was removed from benzylthio adduct to C45H36O18. Peak D was suggested to be an A-B type trimer similar to peak B but with a benzylthio adduct.
- The parental mass of peak F was [M-H]− at m/z 605.1449 and its MS/MS was [M-H]− at m/z 481.1109, so that a benzylthio adduct was also present in peak F. However, the predicted formula could not be obtained from the parental mass. Since the predicted formula of peak F was undefined, peak F is indicated as “unknown” in TABLE 3.
- The thiolysates of PAC from blueberry leaves were obtained free AB-type trimer, benzylthio adducts of AB-type trimer and A-type dimer other than flavan-3-ol monomer and flavan-3-ol benzylthioether. Since the constitution ratio of flavan-3-ol oligomer and their benzylthio adducts were high relatively, a calculating formula of mDP was modified.
- The mean degree of polymerization (mDP) was calculated by the formula, mDP=[sum of (benzylthio adducts×n)+sum of (free flavan-3-ol×n)]/[total free flavan-3-ol], which “n” is DP of detected flavan-3-ol by thiolysis. Moreover, peak area of detected flavan-3-ol benzylthio adducts were corrected from thiolysates of procyanidin B2 preparation.
- The structural analysis of HCV inhibitor PAC from blueberry leaves (LC3) is summarized in TABLE 3. The mDP of PAC in this fraction was estimated to be 7.7. The PAC from LC3 fraction was composed of primarily epicatechin, which was 65.1% and 58.1% in terminal units and extension respectively. In addition, the monomer composition of the A-type dimer and the AB-type trimer were unknown. Therefore, when flavan-3-ol monomer proportion was re-calculated only in detected monomers, 95% of the PAC from LC3 was composed of epicatechin.
-
TABLE 3 Thiolysis Results of Purified Fraction (LC3) from Blueberry Leaves Terminal (%) Extension (%) mDP C EC AB-3 Total C EC A-2 Unknown AB-3 Total LC3 7.7 20.4 65.1 14.5 100 0.8 58.1 11.9 23.2 6.0 100
Notes: c; catechin, EC; epicatechin, AB-3; trimer consisting of both A-type and B-type interflavan bonds, A-2; A-type dimer. - 1. PAC Preparation from Various Materials
- From results of example 1, the proanthocyanidin (PAC) was identified as compound possessing the suppression activity of HCV replication. PAC is previously known as condensed tannin and contained in various plants and foods. It has been already reported that the following materials contain PAC, so, PAC fraction can be separated from these materials.
-
Sample 1; blueberry leaves -
Sample 2; blueberry fruit -
Sample 3; taro peel -
Sample 4; pine bark extract (Pycnogenol™) -
Sample 5; grape seed extract (Gravinol™) -
Sample 6; apple polyphenol (Applephenol™) -
Sample 7; cranberry (cranberry powder) -
Sample 8; strawberry fruit -
Sample 9; peanut peel -
Sample 10; croton sap (Sangre de Drago, Raintree Nutrition Inc.) - (Separation of PAC Fraction from Blueberry Leaves: Sample 1)
- 10 g of the lyophilized powder of rabbit-eye blueberry (Vaccinium virgatum Aiton) leaves was extracted with 100 ml of hexane for 30 min and the supernatant therefrom was decanted. This procedure was repeated three times, followed by washing in 100 ml of ethyl acetate for 30 min three times. The remaining residues were extracted with 100 ml of methanol for 30 min, and its supernatant was decanted and filtered. This procedure was repeated four times and the resulting crude methanol extracts were concentrated by rotary evaporator at 50° C. and lyophilized, finally resulting in approximately 3.5 g of solid powder.
- The crude methanol extract (approx. 500 mg) was then dissolved in 60% methanol and placed on a Sephadex LH-20 column (50 mm×50 mm; GE Healthcare). In fractionation, the following series of solvents was used: 400 ml of 60% methanol; 400 ml of 100% methanol; 400 ml of 70% acetone. Each eluent were concentrated by evaporator and lyophilized, finally resulting in approximately 100 mg of solid PAC.
- (Preparation of PAC Fraction from
Sample 2˜10) -
Sample Sample 4 to 8 and 10 was prepared from purchased materials containing PAC. All materials were extracted with 100% methanol, and concentrated by evaporator and lyophilized. Then each PAC preparations were processed by the same method aforementioned using Sephadex LH-20. - 2. Composition Analysis of PAC Preparations
- PAC samples prepared from each origin were analyzed by Porter method and thiolysis. Replicon cells were assayed for replication suppressive activity. These results are summarized as TABLE 4-6.
- Table 6 shows the HCV replication suppressive activity, PAC contents and the compositions of propelargonidin (PP), procyanidin (PC) and prodelphinidin (PD) which were calculated from results of thiolysis. In the samples showing no PAC contents value of table 6, there were detected little quantity of the yielding PAC.
- The mDP value of PAC preparations from blueberries (
Sample 1 or 2) was around 12 and their composition had epicatechin-rich structure and A-type of interflavan bond. The mDP of PAC from taro peel (Sample 3) was 10.5 and the most of them were epicatechin and possessed A-type bond. In pycnogenol, mDP was approximately 6.5, and epicatechin was high in composition ratio of extension units, but it was high catechin in that of terminal units. - The gravinol (Sample 5) was characterized by that the mDP value had relatively-long about 14.4, and the composition ratio of epicatechin-gallate was high in comparison with others. The mDP value of the applephenon (Sample 6) was approx. 4.4, same long as that of strawberry (Sample 8). Moreover, both samples (
Sample 6 and 8) possessed high ratio of epicatechin composition, but epiafzelechin content was approximately 10% detected only in the strawberry (sample 8). The mDP of the cranberry fruit (Sample 7) and the peanut peel (Sample 9) were 6.6 and 7.4 respectively, and both samples had comparatively high ratio of A-type interflavan bond. The croton sap (Sample 10) was characterized in that the mDP value was 8.3 and the composition ratio of epicatechin was high, but gallocatechin and epigallocatechin were detected only in the PAC from the croton sap (sample 10), and the ratio became to 37.4% when gallocatechins were converted into prodelphinidin. - In HCV replication suppressive activities, the IC50 value of
sample 1 to 9 were less than 1.0 μg/ml, and the ratio was more than 10. It leads to the conclusion in which these samples could be evaluated to have the suppressive activity on HCV replication. But, in case of the croton sap (sample 10), the IC50 was more than 1.0 μg/ml, and the ratio of that was less than 10, so that this was evaluated to have no activity. - From these results, almost all PAC from various plant origins were identified to have HCV replication suppressive activity in replicon cells, except PAC containing much prodelphinidin (PD) composition ratios such as croton sap (sample 10), because it could not be confirmed to has the suppressive activity.
-
TABLE 4 The mDP and Composition of PAC Preparations by Thiolysis Terminal Units Af EAf C EC GC EGC A-2 AB-3 mDP (%) (%) (%) (%) (%) (%) (%) (%) Total Blueberry Leaf 11.2 — — 31.2 42.6 — — — 26.2 100 Blueberry Fruit 12.6 — — 43.6 56.4 — — — — 100 Taro Peel 10.5 — — — 100.0 — — — — 100 Pycnogenol 6.5 — — 96.4 3.6 — — — — 100 Gravinol 14.4 — — 61.7 38.3 — — — — 100 Applephenon 4.4 — — 10.7 89.3 — — — — 100 Cranberry Fruit 6.6 — — — 41.8 — — 58.2 — 100 Strawberry 4.4 — 25.5 33.4 41.0 — — — — 100 Fruit Peanuts Peel 7.4 — — 8.7 8.9 — — 77.0 5.4 100 Croton Sap 8.3 — — — 36.0 4.5 59.5 — — 100 -
TABLE 5 The mDP and Composition of PAC Preparations by Thiolysis Extension Units Af EAf C EC GC EGC Cg ECg Unknown A-2 AB-3 (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) Total Blueberry Leaf — — — 69.6 — — — — 8.2 13.3 8.9 100 Blueberry Fruit — — — 85.6 — — — — 3.7 6.2 4.6 100 Taro Peel — — — 90.8 — — — — — 8.2 1.0 100 Pycnogenol — — 16.9 83.1 — — — — — — — 100 Gravinol — — 8.7 41.7 — — 2.8 46.8 — — — 100 Applephenon — — 3.5 94.1 — — — 2.4 — — — 100 Cranberry Fruit — — 1.4 68.5 — — — — — 19.5 10.5 100 Strawberry 0.7 4.9 19.0 75.4 — — — — — — — 100 Fruit Peanuts Peel — — 7.3 44.4 — — — — — 24.7 23.6 100 Croton Sap — 2.7 12.4 51.1 16.8 16.9 — — — — — 100 - Af; afzelechin, EAf; epiafzelechin, C; catechin, EC; epicatechin, GC; gallocatechins, EGC; Epigallocatechin, Cg; catechin-gallate, ECg; epicatechin-gallate, A-2; A-type dimer, AB-3; trimer consisting of both A-type and B-type interflavan bond.
-
TABLE 6 Anthocyanidin Components and Replicon Assay of PAC Preparations Composition Replicon Assay PAC PP PC PD IC50 CC50 Content (%) (%) (%) (μg/ml) (μg/ml) Ratio (%) Blueberry Leaf — 100.0 — 0.56 16.26 29.0 88.1 Bluebeny Fruit — 100.0 — 0.25 15.03 60.1 — Taro Peel — 100.0 — 0.18 13.24 73.6 80.6 Pycnogenol — 100.0 — 0.56 18.88 33.7 65.0 Gravinol — 100.0 — 0.20 9.95 49.8 55.9 Applephenon — 100.0 — 0.61 22.26 36.5 60.6 Cranberry Fruit — 100.0 — 0.31 15.95 51.5 — Strawberry 10.2 89.8 — 0.20 11.70 58.5 52.1 Fruit Peanuts Peel — 100.0 — 0.11 9.01 81.9 96.8 Croton Sap 2.4 60.2 37.4 5.89 23.62 4.0 64.9
PP; propelargonidin, PC; procyanidin, PD; prodelphinidin - To prepare PAC from blueberry leaves, freeze-dried powder (105 g) was extracted with 1.2 liters of acetone for 10 min and the supernatant obtained was then decanted. This procedure was repeated five times to remove the green pigment from the leaves, followed by washing in 1.2 liters of hexane for 10 min. The remaining residues were washed with ethyl acetate. The washed powder of leaves was further extracted with 1.2 liters of methanol for 30 min, and the supernatant obtained was then filtered. This procedure was repeated four times and the resulting crude methanol extracts were concentrated by rotary evaporator at 50° C. and lyophilized, finally resulting in approximately 30 g of solid powder.
- The crude methanol extract (15 g) was then dissolved in 1.0 liters of 60% methanol and placed on a Sephadex LH-20 column (50 mm×920 mm; GE Healthcare). Fractionation was performed using the following series of solvents: fraction I, 9.0 L of 60% methanol (retrieved weight: 10.2 g); fraction II, 9.0 L of 100% methanol (retrieved weight: 3.3 g); fraction III, 9.0 L of 70% acetone (retrieved weight: 1.3 g). In each fraction, the eluate was divided into 28 sub-fractions per liter.
- After fractionation on a Sephadex LH-20 column, each eluate was thiolysed to determine the components and mDP of PAC (
FIG. 11 ). Then, PAC with different mDP from blueberry leaves was assessed for the inhibitory activity of HCV replication. The HCV replication suppressive activity of PAC from blueberry leaves was clearly dependent on polymerization degree level and the apex activity was observed at a polymerization degree level of around 8 to 9. In this illustrative embodiment, mDP of PAC was preferably at least 5. - (Discussion)
- In
FIG. 4 to 6 , when the prodelphinidin units (R1=R2=R3=OH) is high in PAC composition, the IC50 value ofSample 10 is more than 1.0 μg/ml and the ratio is less than 10, so that it is not able to use as anti-HCV agent. In PAC composition of this invention, the degree of polymerization is more than or equal to 3, and delphinidin content was low, so that HCV replication inhibition activity became strong, namely it is useful as anti-HCV agent. - The HCV production suppressant of this invention possesses the superior anti-HCV effect, so that it is applied to therapeutic medicine or dietary supplements of hepatic disorders from HCV, instead of the interferon therapy.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/204,219 US8846751B2 (en) | 2008-09-03 | 2011-08-05 | Agent for inhibiting production of hepatitis C virus and its use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008226425A JP4892690B2 (en) | 2008-09-03 | 2008-09-03 | Hepatitis C virus production inhibitor |
JP2008-226425 | 2008-09-03 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/204,219 Division US8846751B2 (en) | 2008-09-03 | 2011-08-05 | Agent for inhibiting production of hepatitis C virus and its use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100055065A1 true US20100055065A1 (en) | 2010-03-04 |
Family
ID=41725769
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/546,281 Abandoned US20100055065A1 (en) | 2008-09-03 | 2009-08-24 | Agent for inhibiting production of hepatitis c virus and its use |
US13/204,219 Expired - Fee Related US8846751B2 (en) | 2008-09-03 | 2011-08-05 | Agent for inhibiting production of hepatitis C virus and its use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/204,219 Expired - Fee Related US8846751B2 (en) | 2008-09-03 | 2011-08-05 | Agent for inhibiting production of hepatitis C virus and its use |
Country Status (2)
Country | Link |
---|---|
US (2) | US20100055065A1 (en) |
JP (1) | JP4892690B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110158933A1 (en) * | 2009-12-30 | 2011-06-30 | Industrial Technology Research Institute (Itri) | Liver function and treatment of liver disease |
WO2012130893A1 (en) | 2011-03-28 | 2012-10-04 | Centre National De La Recherche Scientifique (C.N.R.S) | Use of epigallocatechin gallate as an antiviral agent against infections by the hepatitis c virus |
WO2014210391A1 (en) * | 2013-06-26 | 2014-12-31 | Dianaplantsciences, Inc. | Incorporation of cultured bilberry cells in cosmetics, dietary supplements, and/or functional foods |
CN104628697A (en) * | 2013-11-15 | 2015-05-20 | 李锦梁 | Process for extracting raw anthocyanosides |
EP2999468A4 (en) * | 2013-05-20 | 2017-01-18 | Indus Biotech Private Limited | A method of managing hepatic fibrosis, hepatitis c virus and associated condition |
CN109096236A (en) * | 2018-08-13 | 2018-12-28 | 安徽兆龙生物科技有限公司 | Blueberry procyanidine biological extraction process |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012250940A (en) * | 2011-06-03 | 2012-12-20 | Kumamoto Univ | Composition for preventing, treating or improving hepatitis c virus |
JP6742965B2 (en) * | 2016-07-29 | 2020-08-19 | ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company | Use of compositions containing tannins |
TWI611806B (en) * | 2016-11-15 | 2018-01-21 | 景鑫生物科技股份有限公司 | A use of an extract of asplenium australasicum (j. sm.) hook. |
WO2019204471A1 (en) * | 2018-04-20 | 2019-10-24 | Yale University | Treatment of hepatitis c |
WO2022205137A1 (en) * | 2021-03-31 | 2022-10-06 | 贝尔克斯生技股份有限公司 | Polymeric proanthocyanidin composition and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5211944A (en) * | 1990-10-12 | 1993-05-18 | Shaman Pharmaceuticals, Inc. | Proanthocyanidin polymers having antiviral activity and methods of obtaining same |
US6800433B1 (en) * | 1999-04-23 | 2004-10-05 | Kyowa Hakko Kogyo Co., Ltd. | Process for purification of proanthocyanidin oligomer |
US20080044453A1 (en) * | 2003-09-26 | 2008-02-21 | Kirin Beer Kabushiki Kaisha | Therapeutic Agent for Treatment of Autoimmune Diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6960360B2 (en) | 2000-08-31 | 2005-11-01 | Phenolics, Llc | Efficient method for producing compositions enriched in total phenols |
JP2003277271A (en) * | 2002-03-26 | 2003-10-02 | Norioki Ko | Anticancer drug |
JP2005239581A (en) * | 2004-02-24 | 2005-09-08 | Otsuka Pharmaceut Co Ltd | Composition for preventing, treating or improving myocarditis |
JP4586119B2 (en) * | 2005-10-28 | 2010-11-24 | 独立行政法人科学技術振興機構 | Hepatitis C virus production suppression material and its production method |
-
2008
- 2008-09-03 JP JP2008226425A patent/JP4892690B2/en not_active Expired - Fee Related
-
2009
- 2009-08-24 US US12/546,281 patent/US20100055065A1/en not_active Abandoned
-
2011
- 2011-08-05 US US13/204,219 patent/US8846751B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5211944A (en) * | 1990-10-12 | 1993-05-18 | Shaman Pharmaceuticals, Inc. | Proanthocyanidin polymers having antiviral activity and methods of obtaining same |
US6800433B1 (en) * | 1999-04-23 | 2004-10-05 | Kyowa Hakko Kogyo Co., Ltd. | Process for purification of proanthocyanidin oligomer |
US20080044453A1 (en) * | 2003-09-26 | 2008-02-21 | Kirin Beer Kabushiki Kaisha | Therapeutic Agent for Treatment of Autoimmune Diseases |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110158933A1 (en) * | 2009-12-30 | 2011-06-30 | Industrial Technology Research Institute (Itri) | Liver function and treatment of liver disease |
US9474735B2 (en) | 2009-12-30 | 2016-10-25 | Industrial Technology Research Institute (Itri) | Liver function improvement and treatment of liver disease |
WO2012130893A1 (en) | 2011-03-28 | 2012-10-04 | Centre National De La Recherche Scientifique (C.N.R.S) | Use of epigallocatechin gallate as an antiviral agent against infections by the hepatitis c virus |
EP2999468A4 (en) * | 2013-05-20 | 2017-01-18 | Indus Biotech Private Limited | A method of managing hepatic fibrosis, hepatitis c virus and associated condition |
WO2014210391A1 (en) * | 2013-06-26 | 2014-12-31 | Dianaplantsciences, Inc. | Incorporation of cultured bilberry cells in cosmetics, dietary supplements, and/or functional foods |
CN104628697A (en) * | 2013-11-15 | 2015-05-20 | 李锦梁 | Process for extracting raw anthocyanosides |
CN109096236A (en) * | 2018-08-13 | 2018-12-28 | 安徽兆龙生物科技有限公司 | Blueberry procyanidine biological extraction process |
Also Published As
Publication number | Publication date |
---|---|
US8846751B2 (en) | 2014-09-30 |
JP2010059096A (en) | 2010-03-18 |
JP4892690B2 (en) | 2012-03-07 |
US20110288164A1 (en) | 2011-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8846751B2 (en) | Agent for inhibiting production of hepatitis C virus and its use | |
Albuquerque et al. | Jabuticaba residues (Myrciaria jaboticaba (Vell.) Berg) are rich sources of valuable compounds with bioactive properties | |
US10183007B2 (en) | Method of producing proanthocyanidin oligomer | |
Islam | Sweetpotato (Ipomoea batatas L.) leaf: its potential effect on human health and nutrition | |
EP0925068B1 (en) | Use of a pharmaceutical composition containing polyphenols from grapes or from wine, in particular resveratrol, and yeast extracts | |
JP2002524480A (en) | Bioflavonoids as hypoglycemic agents | |
JP2009286796A (en) | Method for producing and using antineoplastic cocoa extract | |
KR100428936B1 (en) | Health improving Spice Composition | |
KR101406201B1 (en) | Ingenane type diterpene compound and a pharmaceutical composition for treatment and prevention of virus infection comprising the same | |
Bhardwaj et al. | Phytochemicals and antioxidant activity in Boerhavia diffusa | |
WO2004030683A1 (en) | Remedies | |
JP2008156265A (en) | A-type proanthocyanidin oligomer fraction and method for producing the same | |
JP4822291B2 (en) | Liver fibrosis inhibitor | |
EP2792666B1 (en) | Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same | |
JP2007531734A (en) | Passion fruit extract and use thereof | |
AU2013210416A1 (en) | Desrhamnosyl acteoside-containing olive extract | |
AU2003252716A1 (en) | Food improving blood flow | |
Asif | Bioactive phytochemical constituents of some edible fruits of myrtaceae family | |
JP2010270096A (en) | Glucose absorption inhibitor | |
KR100314477B1 (en) | Composition for improving lipid metabolism and decreasing bllod pressure which comprises jujube and citrus peel extracts | |
US7332522B2 (en) | Liver function protecting or ameliorating agent | |
KR101305555B1 (en) | Composition for treatment and prevention of bone diseases comprising extract of magnoliae flos's active components | |
KR100296250B1 (en) | Composition for improving lipid metabolism and lowering blood pressure containing jujube extract and tangerine pericarp extract | |
Thepthanee et al. | Evaluation of Phytochemical Contents and In Vitro Antioxidant, Anti-Inflammatory, and Anticancer Activities of Black Rice Leaf (Oryza sativa L.) Extract and Its Fractions. Foods. 2021; 10 (12): 2987 | |
KR101320975B1 (en) | Composition for treatment and prevention of bone diseases comprising extract of magnoliae flos's active components |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MIYAZAKI PREFECTURAL INDUSTRIAL SUPPORT FOUNDATION Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAKESHITA, MASAHIKO;TSUBOUCHI, HIROHITO;UTO, HIROFUMI;AND OTHERS;SIGNING DATES FROM 20090930 TO 20091008;REEL/FRAME:023470/0021 Owner name: MIYAZAKI PREFECTURE,JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAKESHITA, MASAHIKO;TSUBOUCHI, HIROHITO;UTO, HIROFUMI;AND OTHERS;SIGNING DATES FROM 20090930 TO 20091008;REEL/FRAME:023470/0021 Owner name: UNKAI SHUZO CO., LTD.,JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAKESHITA, MASAHIKO;TSUBOUCHI, HIROHITO;UTO, HIROFUMI;AND OTHERS;SIGNING DATES FROM 20090930 TO 20091008;REEL/FRAME:023470/0021 Owner name: MINAMI NIPPON DAIRY CO-OP CO., LTD.,JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAKESHITA, MASAHIKO;TSUBOUCHI, HIROHITO;UTO, HIROFUMI;AND OTHERS;SIGNING DATES FROM 20090930 TO 20091008;REEL/FRAME:023470/0021 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |